JP2000273083A - Prostaglandin derivative - Google Patents
Prostaglandin derivativeInfo
- Publication number
- JP2000273083A JP2000273083A JP11076837A JP7683799A JP2000273083A JP 2000273083 A JP2000273083 A JP 2000273083A JP 11076837 A JP11076837 A JP 11076837A JP 7683799 A JP7683799 A JP 7683799A JP 2000273083 A JP2000273083 A JP 2000273083A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- methyl ester
- pgf
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003180 prostaglandins Chemical class 0.000 title claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 5
- 125000005843 halogen group Chemical group 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims description 9
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 claims description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 74
- 150000004702 methyl esters Chemical class 0.000 abstract description 57
- -1 ethylene, trans-vinylene, ethynylene Chemical group 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 2
- 208000010412 Glaucoma Diseases 0.000 abstract description 2
- 206010019280 Heart failures Diseases 0.000 abstract description 2
- 206010020772 Hypertension Diseases 0.000 abstract description 2
- 239000000556 agonist Substances 0.000 abstract description 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract description 2
- 229910052736 halogen Inorganic materials 0.000 abstract description 2
- 230000007062 hydrolysis Effects 0.000 abstract description 2
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 2
- 208000017169 kidney disease Diseases 0.000 abstract description 2
- 238000010511 deprotection reaction Methods 0.000 abstract 1
- 230000026030 halogenation Effects 0.000 abstract 1
- 238000005658 halogenation reaction Methods 0.000 abstract 1
- 208000023589 ischemic disease Diseases 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 230000009467 reduction Effects 0.000 abstract 1
- 238000006722 reduction reaction Methods 0.000 abstract 1
- 230000000707 stereoselective effect Effects 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 51
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 42
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 29
- 239000000243 solution Substances 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- FGOJCPKOOGIRPA-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 5-oxoazepane-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CCC1=O FGOJCPKOOGIRPA-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- ZKGVUSYUOCBPQO-UHFFFAOYSA-M [I-].COC(=O)CCCCC[Zn+] Chemical compound [I-].COC(=O)CCCCC[Zn+] ZKGVUSYUOCBPQO-UHFFFAOYSA-M 0.000 description 4
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 4
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- XVYSDYTXFALKHU-UHFFFAOYSA-M [I-].COC(=O)CSCCC[Zn+] Chemical compound [I-].COC(=O)CSCCC[Zn+] XVYSDYTXFALKHU-UHFFFAOYSA-M 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- LQMDOONLLAJAPZ-UHFFFAOYSA-N 1-ethynylcyclopentan-1-ol Chemical compound C#CC1(O)CCCC1 LQMDOONLLAJAPZ-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- MLTYLUWRSURSNP-UHFFFAOYSA-N COC(=O)CCCCC[Zn+] Chemical compound COC(=O)CCCCC[Zn+] MLTYLUWRSURSNP-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- CDSQKRACHNDYOX-UHFFFAOYSA-N cyclohexyloxy(triethyl)silane Chemical compound CC[Si](CC)(CC)OC1CCCCC1 CDSQKRACHNDYOX-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000003682 fluorination reaction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- JHSGLPOTEFPLMB-UHFFFAOYSA-N triethyl-(1-ethynylcycloheptyl)oxysilane Chemical compound CC[Si](CC)(CC)OC1(C#C)CCCCCC1 JHSGLPOTEFPLMB-UHFFFAOYSA-N 0.000 description 2
- SQCUVSSAYWYSRX-UHFFFAOYSA-N triethyl-(1-ethynylcyclohexyl)oxysilane Chemical compound CC[Si](CC)(CC)OC1(C#C)CCCCC1 SQCUVSSAYWYSRX-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- UEPOKNWIWRACBZ-AWEZNQCLSA-N (4r)-4-[tert-butyl(dimethyl)silyl]oxy-2-(diethylaminomethyl)cyclopent-2-en-1-one Chemical compound CCN(CC)CC1=C[C@H](O[Si](C)(C)C(C)(C)C)CC1=O UEPOKNWIWRACBZ-AWEZNQCLSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- QKJJSXGDSZZUKI-UHFFFAOYSA-N 1-ethynylcycloheptan-1-ol Chemical compound C#CC1(O)CCCCCC1 QKJJSXGDSZZUKI-UHFFFAOYSA-N 0.000 description 1
- QYLFHLNFIHBCPR-UHFFFAOYSA-N 1-ethynylcyclohexan-1-ol Chemical compound C#CC1(O)CCCCC1 QYLFHLNFIHBCPR-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- RZXUYICBUKWHGW-UHFFFAOYSA-N COC(=O)CCCCC[Zn] Chemical compound COC(=O)CCCCC[Zn] RZXUYICBUKWHGW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- VJXXAAJTXLCJAI-UHFFFAOYSA-M [I-].C(CCC=C)[Zn+] Chemical compound [I-].C(CCC=C)[Zn+] VJXXAAJTXLCJAI-UHFFFAOYSA-M 0.000 description 1
- NODVEIFVSISHMV-UHFFFAOYSA-M [I-].COC(=O)C#CCCC[Zn+] Chemical compound [I-].COC(=O)C#CCCC[Zn+] NODVEIFVSISHMV-UHFFFAOYSA-M 0.000 description 1
- TZZNIOLYJLQQGH-TXOOBNKBSA-M [I-].COC(=O)\C=C\CCC[Zn+] Chemical compound [I-].COC(=O)\C=C\CCC[Zn+] TZZNIOLYJLQQGH-TXOOBNKBSA-M 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000004637 bakelite Substances 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ICXXXLGATNSZAV-UHFFFAOYSA-N butylazanium;chloride Chemical compound [Cl-].CCCC[NH3+] ICXXXLGATNSZAV-UHFFFAOYSA-N 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- VIVJNIHMWMVHCG-UHFFFAOYSA-N cyclopentanamine;phenylmethanamine Chemical compound NC1CCCC1.NCC1=CC=CC=C1 VIVJNIHMWMVHCG-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- YNLAOSYQHBDIKW-UHFFFAOYSA-M diethylaluminium chloride Chemical compound CC[Al](Cl)CC YNLAOSYQHBDIKW-UHFFFAOYSA-M 0.000 description 1
- ZSYZSZTWBOHQQK-UHFFFAOYSA-L dilithium;dichloride Chemical compound [Li+].[Li+].[Cl-].[Cl-] ZSYZSZTWBOHQQK-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000012155 injection solvent Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000003328 mesylation reaction Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 1
- 238000007070 tosylation reaction Methods 0.000 description 1
- WILBTFWIBAOWLN-UHFFFAOYSA-N triethyl(triethylsilyloxy)silane Chemical compound CC[Si](CC)(CC)O[Si](CC)(CC)CC WILBTFWIBAOWLN-UHFFFAOYSA-N 0.000 description 1
- LYKWRNFGMUFMSI-UHFFFAOYSA-N triethyl-(1-ethynylcyclopentyl)oxysilane Chemical compound CC[Si](CC)(CC)OC1(C#C)CCCC1 LYKWRNFGMUFMSI-UHFFFAOYSA-N 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は新規なプロスタグラ
ンジン誘導体、その製薬学的に許容される塩又はその水
和物に関する。[0001] The present invention relates to a novel prostaglandin derivative, a pharmaceutically acceptable salt thereof or a hydrate thereof.
【0002】[0002]
【従来の技術】プロスタグランジン(以下PGと称す
る)は微量で種々の重要な生理作用を発揮することか
ら、医薬への応用を意図して天然PGおよび夥しい数の
その誘導体の合成と生物活性の検討が行われてきてお
り、多数の文献をはじめ、特開昭52−100446号
公報、特表平2−502009号などで報告されてい
る。このうち特表平2−502009号には、9位がハ
ロゲンで置換された一群のPG誘導体が開示されてい
る。また、[K-H Thierauchら、ドラッグ・オブ・ザ・
フューチャー(Drug of the Future)、第17巻、第8
09ページ(1992年)]に、PGD2様のアゴニス
ト活性を有しているPG誘導体が報告されている。2. Description of the Related Art Since prostaglandin (hereinafter referred to as PG) exerts various important physiological actions in a very small amount, synthesis and biological activity of natural PG and a large number of its derivatives are intended for pharmaceutical applications. Have been studied and reported in a large number of documents, such as Japanese Patent Application Laid-Open No. Sho 52-100446 and Japanese Patent Application Laid-Open No. 2-502009. Japanese Patent Application Laid-Open No. 502009/1990 discloses a group of PG derivatives in which the 9-position is substituted with halogen. [KH Thierauch et al., Drug of the
Future (Drug of the Future), Volume 17, Volume 8
09 pages (1992)], PG derivatives having an agonist activity of PGD 2 like have been reported.
【0003】[0003]
【発明が解決しようとする課題】本発明の目的は、PG
D2様のアゴニスト活性を有する新規なPG誘導体を提
供することにある。SUMMARY OF THE INVENTION An object of the present invention is to provide a PG
It is to provide novel PG derivatives having a D 2 like agonistic activity.
【0004】[0004]
【課題を解決するための手段】本発明者らは鋭意研究を
進めた結果、13、14位に三重結合を有する下記式
(I)で表される新規プロスタグランジン誘導体が、上
記目的を達成できることを見出し、本発明を完成した。Means for Solving the Problems As a result of intensive studies, the present inventors have found that a novel prostaglandin derivative represented by the following formula (I) having a triple bond at the 13th and 14th positions achieves the above object. We have found that we can do this and completed the present invention.
【0005】すなわち、本発明は、式(I)That is, the present invention provides a compound represented by the formula (I)
【0006】[0006]
【化2】 Embedded image
【0007】(式中、Xはハロゲン原子を示し、Aはエ
チレン基、トランスビニレン基、エチニレン基、OCH
2又はS(O)pCH2を示し、Rは水素原子、C1-10の
直鎖又は分枝鎖状のアルキル基又はC3-10のシクロアル
キル基を示し、mは0〜5の整数を示し、nは1〜8の
整数を示し、pは0〜2の整数を示す。)で表されるプ
ロスタグランジン誘導体、その製薬学的に許容される塩
又はその水和物である。(Where X represents a halogen atom, A represents an ethylene group, a transvinylene group, an ethynylene group, an OCH
2 or S (O) p CH 2 , R represents a hydrogen atom, a C 1-10 linear or branched alkyl group or a C 3-10 cycloalkyl group; It shows an integer, n shows the integer of 1-8, p shows the integer of 0-2. ), A pharmaceutically acceptable salt thereof or a hydrate thereof.
【0008】また、本発明は一般式(I)に示される化
合物しくはその製薬学的に許容される塩又はその水和物
を含有することを特徴とする医薬組成物である。[0008] The present invention is also a pharmaceutical composition containing a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a hydrate thereof.
【0009】本発明において、ハロゲン原子とは、フッ
素原子、塩素原子、臭素原子又はヨウ素原子である。In the present invention, the halogen atom is a fluorine, chlorine, bromine or iodine atom.
【0010】C3-10のシクロアルキル基とは、例えばシ
クロプロピル基、シクロブチル基、シクロペンチル基、
シクロヘキシル基 、シクロヘプチル基などである。The C 3-10 cycloalkyl group includes, for example, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group,
And cyclohexyl and cycloheptyl.
【0011】C1-10の直鎖又は分枝鎖状のアルキル基と
は、例えばメチル基、エチル基、プロピル基、イソプロ
ピル基、ブチル基、イソブチル基、tert−ブチル
基、ペンチル基、イソペンチル基、2−エチルプロピル
基、ヘキシル基、イソヘキシル基、1−エチルブチル
基、ヘプチル基、イソへプチル基、オクチル基、ノニル
基、デシル基などである。The C 1-10 linear or branched alkyl group includes, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl and the like. , 2-ethylpropyl, hexyl, isohexyl, 1-ethylbutyl, heptyl, isoheptyl, octyl, nonyl, decyl and the like.
【0012】製剤学的に許容される塩とは、例えば、ナ
トリウム、カリウムなどのアルカリ金属との塩、カルシ
ウム、マグネシウムなどのアルカリ土類金属との塩、ア
ンモニア、メチルアミン、ジメチルアミン、シクロペン
チルアミン、ベンジルアミン、ピペリジン、モノエタノ
ールアミン、ジエタノールアミン、モノメチルモノエタ
ノールアミン、トロメタミン、リジン、テトラアルキル
アンモニウム、トリス(ヒドロキシメチル)アミノメタ
ンなどとの塩である。Pharmaceutically acceptable salts include, for example, salts with alkali metals such as sodium and potassium, salts with alkaline earth metals such as calcium and magnesium, ammonia, methylamine, dimethylamine, cyclopentylamine Benzylamine, piperidine, monoethanolamine, diethanolamine, monomethylmonoethanolamine, tromethamine, lysine, tetraalkylammonium, tris (hydroxymethyl) aminomethane and the like.
【0013】[0013]
【発明の実施の形態】式(I)の化合物は、例えば以下
の反応式に要約する方法により製造できる。The compounds of formula (I) can be prepared, for example, by the methods summarized in the following schemes.
【0014】[0014]
【化3】 反応式1 Embedded image Reaction formula 1
【0015】[0015]
【化4】 反応式1のつづき Embedded image Continuation of Reaction Formula 1
【0016】(反応式中、A’はエチレン基、トランス
ビニレン基、エチニレン基、OCH2又SCH2を示し、
R1はC1-10の直鎖又は分枝鎖状のアルキル基又はC
3-10のシクロアルキル基を示し、TBSはtert−ブ
チルジメチルシリル基を示し、TESはトリエチルシリ
ル基を示し、X、m、n、pは前記と同意義である。) 上記反応式を説明すると、 (1)まず、佐藤らの方法[ジャーナル・オブ・オーガ
ニック・ケミストリー(J.Org.Chem.),第
53巻、第5590ページ(1988年)]により公知
の式(II)の化合物に、式(III)で示される有機
アルミニウム化合物0.8〜2.0当量を−10〜30
℃、好ましくは0〜10℃で不活性溶媒(例えば、ベン
ゼン、トルエン、テトラヒドロフラン、ジエチルエーテ
ル、塩化メチレン、n−ヘキサンなど)中で反応させる
ことにより立体特異的に式(IV)の化合物を得る。(In the reaction formula, A ′ represents an ethylene group, a transvinylene group, an ethynylene group, OCH 2 or SCH 2 ,
R 1 is a C 1-10 linear or branched alkyl group or C 1-10
3-10 represents a cycloalkyl group, TBS represents a tert-butyldimethylsilyl group, TES represents a triethylsilyl group, and X, m, n, and p are as defined above. (1) First, a well-known formula by the method of Sato et al. [Journal of Organic Chemistry (J. Org. Chem.), Vol. 53, p. 5590 (1988)]. The compound of (II) is added with 0.8 to 2.0 equivalents of the organoaluminum compound represented by the formula (III) for -10 to 30.
Reaction in an inert solvent (e.g., benzene, toluene, tetrahydrofuran, diethyl ether, methylene chloride, n-hexane, etc.) at 0 DEG C., preferably 0 DEG-10 DEG C., to give the compound of formula (IV) stereospecifically. .
【0017】(2)式(IV)の化合物に式(V)で表
される有機銅化合物0.5〜4当量とトリメチルクロロ
シラン0.5〜4.0当量とを不活性溶媒(例えばベン
ゼン、トルエン、テトラヒドロフラン、ジエチルエーテ
ル、塩化メチレン、n−ヘキサン、n−ペンタンなど)
中、−78〜40℃で反応させ、さらに無機酸(例えば
塩酸、硫酸、硝酸など)又は有機酸(例えば酢酸、p−
トルエンスルホン酸など)もしくはそのアミン塩(例え
ばp−トルエンスルホン酸ピリジン塩など)を用い、有
機溶媒(例えばアセトン、メタノール、エタノール、イ
ソプロパノール、ジエチルエーテルあるいはこれらの混
合溶媒など)中、0〜40℃にて加水分解することによ
り、立体選択的に式(VI)の化合物を得る。(2) A compound of the formula (IV) is combined with 0.5 to 4 equivalents of the organocopper compound represented by the formula (V) and 0.5 to 4.0 equivalents of trimethylchlorosilane in an inert solvent (for example, benzene, Toluene, tetrahydrofuran, diethyl ether, methylene chloride, n-hexane, n-pentane, etc.)
In the medium, the reaction is carried out at −78 to 40 ° C., and an inorganic acid (eg, hydrochloric acid, sulfuric acid, nitric acid, etc.) or an organic acid (eg, acetic acid, p-
0 to 40 ° C. in an organic solvent (for example, acetone, methanol, ethanol, isopropanol, diethyl ether or a mixed solvent thereof) using toluenesulfonic acid or an amine salt thereof (for example, pyridine salt of p-toluenesulfonic acid). To give the compound of formula (VI) stereoselectively.
【0018】(3)式(VI)の化合物を水素化ホウ素
カリウム、水素化ホウ素ナトリウム、シアノ水素化ホウ
素ナトリウム、水素化トリsec−ブチルホウ素リチウ
ムなどの還元剤0.5〜5当量を不活性溶媒(例えば、
テトラヒドロフラン、ジエチルエーテル、エチルアルコ
ール、メチルアルコールなど)中、−78〜40℃で反
応させ、式(VII)および式(VII’)の化合物を
得る。これらの式(VII)および式(VII’)の化
合物はカラムクロマトグラフィーなど通常用いられる分
離法にて精製することができる。(3) The compound of formula (VI) is inertized with 0.5 to 5 equivalents of a reducing agent such as potassium borohydride, sodium borohydride, sodium cyanoborohydride, lithium trisec-butylborohydride or the like. Solvent (for example,
In tetrahydrofuran, diethyl ether, ethyl alcohol, methyl alcohol, etc.) at −78 to 40 ° C. to obtain compounds of the formulas (VII) and (VII ′). These compounds of the formulas (VII) and (VII ') can be purified by a commonly used separation method such as column chromatography.
【0019】(4)式(VII)(または式(VI
I’))の化合物を、例えばメタンスルホニルクロリド
あるいはp−トルエンスルホニルクロリド1〜6当量を
ピリジンなどの適当な溶媒中、必要に応じて0.8〜6
当量の4−ジメチルアミノピリジン存在下、−20〜4
0℃でメシル化あるいはトシル化した後、テトラ−n−
ブチルアンモニウムクロリド1〜16当量でクロル化し
式(VIII)(または式(VIII’))の化合物
(Xは塩素原子)を得る。ここでブロム化、フッ素化も
通常の方法で行うことができる。例えば、ブロム化は、
1〜10当量の四臭化炭素を用い、トリフェニルホスフ
ィン1〜10当量およびピリジン1〜10当量の存在
下、アセトニトリル中反応させることにより得られる。
フッ素化は例えば、塩化メチレン中、ジエチルアミノサ
ルファートリフロリド(DAST)5〜20当量を反応
させることにより得られる。(4) Formula (VII) (or formula (VI)
The compound of I ′)) is converted, for example, from 1 to 6 equivalents of methanesulfonyl chloride or p-toluenesulfonyl chloride in a suitable solvent such as pyridine to 0.8 to 6
-20 to 4 in the presence of an equivalent amount of 4-dimethylaminopyridine
After mesylation or tosylation at 0 ° C, tetra-n-
Chlorination with 1 to 16 equivalents of butylammonium chloride gives a compound of the formula (VIII) (or (VIII ′)) (X is a chlorine atom). Here, bromination and fluorination can also be performed by a usual method. For example, bromination is
It is obtained by reacting in acetonitrile using 1 to 10 equivalents of carbon tetrabromide in the presence of 1 to 10 equivalents of triphenylphosphine and 1 to 10 equivalents of pyridine.
The fluorination is obtained, for example, by reacting 5 to 20 equivalents of diethylaminosulfur trifluoride (DAST) in methylene chloride.
【0020】(5)式(VIII)(または式(VII
I’))の化合物をフッ化水素酸、ピリジニウム ポリ
(ハイドロゲンフロリド)、塩酸などを用い通常行われ
る条件にて、メタノール、エタノール、アセトニトリル
あるいはこれらの混合溶媒または、これらと水との混合
溶媒中、水酸基の保護基であるtert−ブチルジメチ
ルシリル基およびトリエチルシリル基をはずし、本発明
に係るPG誘導体、式(Ia)(または式(Ia’))
を得る。(5) Formula (VIII) (or formula (VII)
I ′)) The compound of methanol, ethanol, acetonitrile, or a mixed solvent thereof, or a mixed solvent thereof with water under the conditions usually used using hydrofluoric acid, pyridinium poly (hydrogen fluoride), hydrochloric acid, etc. In the reaction, the tert-butyldimethylsilyl group and the triethylsilyl group, which are protecting groups for the hydroxyl group, are removed, and the PG derivative according to the present invention, the formula (Ia) (or the formula (Ia ′))
Get.
【0021】(6)式(Ia)(または式(Ia’))
の化合物を1〜6当量の塩基を用い、通常加水分解に用
いられる溶媒中にて加水分解することにより、本発明に
係るPG誘導体、式(Ib)(または式(Ib’))を
得る。塩基としては、水酸化リチウム、炭酸カリウムな
どが例示され、溶媒としては、アセトニトリル、アセト
ン、メタノール、エタノール、水あるいはこれらの混合
溶媒などが例示される。(6) Formula (Ia) (or Formula (Ia '))
Is hydrolyzed in a solvent usually used for hydrolysis using 1 to 6 equivalents of a base to obtain a PG derivative according to the present invention, formula (Ib) (or formula (Ib ′)). Examples of the base include lithium hydroxide and potassium carbonate, and examples of the solvent include acetonitrile, acetone, methanol, ethanol, water, and a mixed solvent thereof.
【0022】(7)式(Ib)(または式(Ib’))
の化合物をメタ過ヨウ素酸ナトリウム、過酸化水素水、
過酢酸、m−クロロ過安息香酸、tert−ブチルヒド
ロペルオキシドなどの酸化剤を用い、ジエチルエーテ
ル、メタノール、エタノール、塩化メチレン、水あるい
はこれらの混合溶媒中、−20〜50℃で反応させ、本
発明に係るPG誘導体、式(Ic)(または式(I
c’))を得る。(7) Formula (Ib) (or Formula (Ib '))
Compound of sodium metaperiodate, aqueous hydrogen peroxide,
Using an oxidizing agent such as peracetic acid, m-chloroperbenzoic acid, or tert-butyl hydroperoxide, the reaction is carried out at -20 to 50 ° C in diethyl ether, methanol, ethanol, methylene chloride, water or a mixed solvent thereof. The PG derivative according to the invention, the formula (Ic) (or the formula (I
c ′)) is obtained.
【0023】(8)式(Ic)(または式(Ic’))
の化合物を(6)と同様に塩基を用いて、加水分解する
ことにより、本発明に係るPG誘導体、式(Id)(ま
たは式(Id’))が得られる。また、式(Ib)(ま
たは式(Ib’))の化合物を用い、(7)と同様にし
て酸化することによっても本発明に係るPG誘導体、式
(Id)(または式(Id’))を得ることができる。(8) Formula (Ic) (or Formula (Ic '))
Is hydrolyzed using a base in the same manner as in (6) to obtain a PG derivative according to the present invention, formula (Id) (or formula (Id ')). The PG derivative according to the present invention, a compound of formula (Id) (or formula (Id ')) can also be obtained by oxidizing the compound of formula (Ib) (or formula (Ib')) in the same manner as in (7). Can be obtained.
【0024】なお、α鎖中のS(O)pは、p=1のと
きはNote that S (O) p in the α chain is as follows when p = 1.
【0025】[0025]
【化5】 Embedded image
【0026】を表し、p=2のときはAnd when p = 2,
【0027】[0027]
【化6】 Embedded image
【0028】を表す。Represents the following.
【0029】本発明の化合物は、全身的または局所的に
経口または非経口的に慣用の投与剤型で投与することが
できる。これらは、例えば、通常の方法により製造する
ことができる錠剤、粉剤、顆粒剤、散剤、カプセル剤、
液剤、乳剤、懸濁剤等の形で経口投与することができ
る。静脈内投与の製剤としては、水性または非水性溶液
剤、乳剤、懸濁剤、使用直前に注射溶媒に溶解して使用
する固形製剤等を用いることができる。また、本発明の
化合物は、α、βもしくはγ−シクロデキストリンまた
はメチル化シクロデキストリン等と包接化合物を形成さ
せて製剤化することもできる。更に、その水性または非
水性溶液剤、乳剤、懸濁剤等を注射等により投与するこ
とができる。投与量は年齢、体重等により異なるが、成
人に対し1ng〜1mg/日であり、これを1日1回ま
たは数回に分けて投与する。The compounds of the present invention can be administered systemically or topically orally or parenterally in conventional dosage forms. These are, for example, tablets, powders, granules, powders, capsules, which can be produced by ordinary methods.
It can be administered orally in the form of a solution, emulsion, suspension or the like. As preparations for intravenous administration, aqueous or non-aqueous solutions, emulsions, suspensions, solid preparations used by dissolving in an injection solvent immediately before use, and the like can be used. The compound of the present invention can also be formulated by forming an inclusion compound with α, β or γ-cyclodextrin or methylated cyclodextrin. Further, the aqueous or non-aqueous solution, emulsion, suspension and the like can be administered by injection or the like. The dose varies depending on the age, body weight, etc., but is 1 ng to 1 mg / day for an adult, and is administered once or several times a day.
【0030】本発明に係る代表的な式(I)の化合物と
して表1の化合物を挙げることができる。The typical compounds of the formula (I) according to the present invention include the compounds shown in Table 1.
【0031】[0031]
【表1】 表1 [Table 1] Table 1
【0032】[0032]
【表2】 表1のつづき [Table 2] Continued from Table 1
【0033】[0033]
【発明の効果】本発明は、優れたプロスタグランジンD
2様のアゴニスト作用を示し、腎疾患および虚血性心疾
患、心不全、高血圧などの循環器疾患および緑内障に対
して有用である。以下、本発明の効果を試験例を挙げて
より具体的に説明する。The present invention provides an excellent prostaglandin D
It exhibits two types of agonistic action and is useful for renal diseases and ischemic heart diseases, heart failure, cardiovascular diseases such as hypertension, and glaucoma. Hereinafter, the effects of the present invention will be described more specifically with reference to test examples.
【0034】試験例 ウシ胎児気管由来細胞EBTr[NBL−4]における
cAMP酸性促進作用の測定 24ウェルプレート(住友ベークライト社製)に、ウシ
胎児気管由来細胞EBTr[NBL−4](大日本製薬
社製)を6×104セル/ウェルで撒き、増殖培地(1
0%コウシ血清、2mMグルタミン、非必須アミノ酸を
含むMEMアール培地)で48時間培養した。続いて、
被験化合物および0.5mMの3−イソブチル−1−メ
チルキサンチンを含む0.5mlの増殖培地で15分間
培養した。反応終了後、細胞をリン酸緩衝液(Ca++,
Mg++不含)で洗浄し、65%エタノール水溶液0.6
mlを加え4℃で1時間放置し、生成したcAMPを抽
出した。溶媒を遠心エバポレーターで留去した後、cA
MP量をcAMP EIASystem(アマシャム社
製)を用いて測定した。Test Example Measurement of cAMP Acid-Promoting Activity in Bovine Fetal Tracheal Derived Cell EBTr [NBL-4] Bovine fetal tracheal derived cell EBTr [NBL-4] (Dainippon Pharmaceutical Co., Ltd.) was placed in a 24-well plate (Sumitomo Bakelite). Was spread at 6 × 10 4 cells / well, and the growth medium (1
The cells were cultured for 48 hours in 0% calf serum, 2 mM glutamine, and a MEM R medium containing non-essential amino acids. continue,
The cells were cultured for 15 minutes in 0.5 ml of a growth medium containing the test compound and 0.5 mM of 3-isobutyl-1-methylxanthine. After the reaction was completed, the cells were washed with a phosphate buffer (Ca ++ ,
(Without Mg ++ ), 0.6% aqueous 65% ethanol
Then, the resulting cAMP was extracted at 4 ° C. for 1 hour. After the solvent was distilled off with a centrifugal evaporator, cA
The amount of MP was measured using cAMP EIASystem (manufactured by Amersham).
【0035】この結果を表2に示す。Table 2 shows the results.
【0036】[0036]
【表3】 表2 [Table 3] Table 2
【0037】注)表中の化合物8は、後記実施例で製造
した化合物である。被験化合物はエタノール溶液とし、
コントロールは溶媒処理群として比較を行った。Note) Compound 8 in the table is a compound produced in the following Examples. The test compound is an ethanol solution,
As a control, comparison was made as a solvent-treated group.
【0038】以上の結果、化合物8は、cAMP産生促
進作用を有することが判る。As a result, it can be seen that Compound 8 has a cAMP production promoting effect.
【0039】[0039]
【実施例】以下、本発明を実施例を挙げてより具体的に
説明する。なお、化合物の命名中、「16,17,1
8,19,20−ペンタノル」の「ノル」とは、その位
置の炭素鎖がないことを意味する。EXAMPLES Hereinafter, the present invention will be described more specifically with reference to examples. In the compound naming, “16, 17, 1
“Nor” in “8,19,20-pentanor” means that there is no carbon chain at that position.
【0040】参考例1 1−エチニル−1−トリエチルシロキシシクロペンタン 1−エチニル−1−ヒドロキシシクロペンタン(5.4
5g,49.5mmol)のジメチルホルムアミド(4
9.5ml)溶液に、室温でイミダゾール(6.74
g,99.0mmol)およびトリエチルクロロシラン
(9.97ml,59.4mmol)を加え、30分間
撹拌した。反応液をn−ヘキサン:飽和重曹水に加え、
有機層を分離した。水層をヘキサン抽出した後、有機層
を合わせて飽和重曹水で洗浄後、無水硫酸マグネシウム
で乾燥した。濾過後、濾液を減圧蒸留して標記化合物
(9.26g)を得た。Reference Example 1 1-ethynyl-1-triethylsiloxycyclopentane 1-ethynyl-1-hydroxycyclopentane (5.4
5 g, 49.5 mmol) of dimethylformamide (4
9.5 ml) solution at room temperature with imidazole (6.74).
g, 99.0 mmol) and triethylchlorosilane (9.97 ml, 59.4 mmol) were added and stirred for 30 minutes. The reaction solution was added to n-hexane: saturated aqueous sodium hydrogen carbonate,
The organic layer was separated. After the aqueous layer was extracted with hexane, the organic layers were combined, washed with saturated aqueous sodium hydrogen carbonate, and dried over anhydrous magnesium sulfate. After filtration, the filtrate was distilled under reduced pressure to obtain the title compound (9.26 g).
【0041】b.p. 98℃/10.0 torr.1 H−NMR(CDCl3,200MHz)δppm;
0.45−1.15(m,15H),1.48−2.0
4(m,8H),2.43(s,1H) IR(neat);3308,2956,2913,2
876,1459,1415,1321,1239,1
204,1116,1059,1008,946,85
0,743,729,655,623,519 c
m-1。B. p. 98 ° C / 10.0 torr. 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.45-1.15 (m, 15H), 1.48-2.0
4 (m, 8H), 2.43 (s, 1H) IR (neat); 3308, 2956, 2913, 2
876, 1459, 1415, 1321, 1239, 1
204, 1116, 1059, 1008, 946, 85
0,743,729,655,623,519 c
m -1 .
【0042】参考例2 1−エチニル−1−トリエチルシロキシシクロヘキサン 参考例1において、1−エチニル−1−ヒドロキシシク
ロペンタンの代わりに1−エチニル−1−ヒドロキシシ
クロヘキサンを用いて、参考例1と同様にして、標記化
合物を得た。REFERENCE EXAMPLE 2 1-Ethynyl-1-triethylsiloxycyclohexane The procedure of Reference Example 1 was repeated, except that 1-ethynyl-1-hydroxycyclohexane was used instead of 1-ethynyl-1-hydroxycyclopentane. To give the title compound.
【0043】b.p. 72℃/0.80 torr.1 H−NMR(CDCl3,200MHz)δppm;
0.58−0.78(m,6H),0.87−1.08
(m,9H),1.14−1.95(m,10H),
2.45(s,1H) IR(neat);3309,2937,2876,1
459,1415,1378,1341,1283,1
240,1150,1155,1105,1058,1
004,950,905,884,868,843,8
15,797,743,728,654,626,55
1,519 cm-1。B. p. 72 ° C./0.80 torr. 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.58-0.78 (m, 6H), 0.87-1.08
(M, 9H), 1.14-1.95 (m, 10H),
2.45 (s, 1H) IR (neat); 3309, 2937, 2876, 1
459,1415,1378,1341,1283,1
240, 1150, 1155, 1105, 1058, 1
004,950,905,884,868,843,8
15,797,743,728,654,626,55
1,519 cm -1 .
【0044】参考例3 1−エチニル−1−トリエチルシロキシ−シクロヘプタ
ン 参考例1において、1−エチニル−1−ヒドロキシシク
ロペンタンの代わりに1−エチニル−1−ヒドロキシシ
クロヘプタンを用いて、参考例1と同様にして、標記化
合物を得た。Reference Example 1 1-ethynyl-1-triethylsiloxy-cycloheptane In Example 1, 1-ethynyl-1-hydroxycycloheptane was used in place of 1-ethynyl-1-hydroxycyclopentane. As above, the title compound was obtained.
【0045】b.p. 82℃/0.67 torr.1 H−NMR(CDCl3,200MHz)δppm;
0.43−0.76(m,6H),0.86−1.04
(m,9H),1.36−2.03(m,12H),
2.43(s,1H) IR(neat);3308,2935,2876,1
459,1415,1378,1282,1239,1
190,1070,1006,835,743,69
0,654,625,544 cm-1。B. p. 82 ° C./0.67 torr. 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.43-0.76 (m, 6H), 0.86-1.04
(M, 9H), 1.36-2.03 (m, 12H),
2.43 (s, 1H) IR (neat); 3308, 2935, 2876, 1
459, 1415, 1378, 1282, 1239, 1
190,1070,1006,835,743,69
0,654,625,544 cm -1 .
【0046】実施例1 9−デオキシ−9β−クロロ−16,17,18,1
9,20−ペンタノル−15,15−ペンタメチレン−
13,14−ジデヒドロ−PGF1α メチルエステル
(化合物7) (1)1−エチニル−1−トリエチルシロキシシクロヘ
キサン(5.58g,23.4mmol)をトルエン
(72ml)に溶解し、0℃でn−ブチルリチウム
(2.5M,ヘキサン溶液、8.6ml)を加え、同温
度で30分間撹拌した。この溶液に0℃でジエチルアル
ミニウムクロリド(0.95M,ヘキサン溶液、26.
5ml)を加え、室温まで30分間撹拌した。この溶液
に室温で(4R)−2−(N,N−ジエチルアミノ)メ
チル−4−(tert−ブチルジメチルシロキシ)シク
ロペント−2−エン−1−オン(0.25M,トルエン
溶液、72ml)を加え、15分間撹拌した。反応液を
ヘキサン(120ml)−飽和塩化アンモニウム水溶液
(170ml)−塩酸水溶液(3M,50ml)の混合
液に撹拌しながら注いだ後、有機層を分離し、飽和重曹
水溶液(50ml)で洗浄した。得られた有機層を無水
硫酸マグネシウムで乾燥、濾過後濃縮して得た残渣をシ
リカカラムクロマトグラフィー(展開溶媒;ヘキサン:
酢酸エチル=49:1)で精製して、(3R,4R)−
2−メチレン−3−[3,3−ペンタメチレン−3−
(トリエチルシロキシ)プロパ−1−イニル]−4−
(tert−ブチルジメチルシロキシ)シクロペンタン
−1−オン(3.07g)を得た。Example 1 9-Deoxy-9β-chloro-16,17,18,1
9,20-pentanor-15,15-pentamethylene-
13,14-didehydro-PGF 1 alpha methyl ester (Compound 7) (1) 1-ethynyl-1-triethylsiloxy cyclohexane (5.58 g, 23.4 mmol) was dissolved in toluene (72 ml), at 0 ° C. n- Butyllithium (2.5 M, hexane solution, 8.6 ml) was added, and the mixture was stirred at the same temperature for 30 minutes. This solution was added to diethylaluminum chloride (0.95 M, hexane solution, 26.degree. C.) at 0.degree.
5 ml) and stirred for 30 minutes to room temperature. At room temperature, (4R) -2- (N, N-diethylamino) methyl-4- (tert-butyldimethylsiloxy) cyclopent-2-en-1-one (0.25 M, toluene solution, 72 ml) was added to this solution. And stirred for 15 minutes. The reaction solution was poured into a mixed solution of hexane (120 ml) -saturated aqueous ammonium chloride solution (170 ml) -hydrochloric acid aqueous solution (3 M, 50 ml) with stirring, and then the organic layer was separated and washed with saturated aqueous sodium bicarbonate solution (50 ml). The obtained organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated, and the resulting residue was subjected to silica column chromatography (eluent: hexane:
Purification with ethyl acetate = 49: 1) gave (3R, 4R)-
2-methylene-3- [3,3-pentamethylene-3-
(Triethylsiloxy) prop-1-ynyl] -4-
(Tert-Butyldimethylsiloxy) cyclopentan-1-one (3.07 g) was obtained.
【0047】1H−NMR(CDCl3,200MHz)
δppm;0.11(s,3H),0.14(s,3
H),0.54−0.73(m,6H),0.80−
1.02(m,9H),0.90(s,9H),0.8
0−1.02(m,9H),1.12−1.90(m,
10H),2.34(dd,J=18.0,7.1H
z,1H),2.74(dd,J=18.0,6.4H
z,1H),3.50−3.62(m,1H),4.2
3−4.37(m,1H),5.57(dd,J=2.
6,0.7Hz,1H),6.17(dd,J=2.
9,0.7Hz,1H) IR(neat);2935,2876,2858,2
209,1736,1715,1621,1462,1
412,1362,1289,1255,1104,1
063,1005,942,905,867,837,
812,779,744,672cm-1。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 0.11 (s, 3H), 0.14 (s, 3
H), 0.54-0.73 (m, 6H), 0.80-
1.02 (m, 9H), 0.90 (s, 9H), 0.8
0-1.02 (m, 9H), 1.12-1.90 (m, 9H)
10H), 2.34 (dd, J = 18.0, 7.1H)
z, 1H), 2.74 (dd, J = 18.0, 6.4H
z, 1H), 3.50-3.62 (m, 1H), 4.2
3-4.37 (m, 1H), 5.57 (dd, J = 2.
6, 0.7 Hz, 1 H), 6.17 (dd, J = 2.
9, 0.7 Hz, 1 H) IR (neat); 2935, 2876, 2858, 2
209, 1736, 1715, 1621, 1462, 1
412, 1362, 1289, 1255, 1104, 1
063, 1005, 942, 905, 867, 837,
812,779,744,672 cm -1 .
【0048】(2)アルゴン気流下、−70℃におい
て、5−カルボメトキシペンチル亜鉛(II)ヨージド
(0.92M,テトラヒドロフラン溶液,3.6ml,
3.3mmol)にシアン化銅(I)・2塩化リチウム
(1.0M,テトラヒドロフラン溶液,2.9ml,
2.9mmol)を加え同温度で20分間撹拌した。こ
の溶液に−70℃で上記(1)で得た化合物(0.25
M,ジエチルエーテル溶液,8.8ml,2.2mmo
l)とクロロトリメチルシラン(0.59ml,3.5
mmol)を加え、撹拌しながら約1時間かけて0℃ま
で昇温した。反応液に飽和塩化アンモニウム水溶液を加
え、ヘキサン抽出した。有機層を飽和重曹水および飽和
食塩水で洗浄後、無水硫酸マグネシウムで乾燥、濾過後
濃縮して得られた残渣をジエチルエーテル(1.76m
l)−イソプロピルアルコール(7.04ml)に溶解
し、p−トルエンスルホン酸ピリジン塩(27.6m
g,0.11mmol)を加え、室温で12時間撹拌し
た。反応液にヘキサンを加え、飽和重曹水および飽和食
塩水で洗浄後、無水硫酸マグネシウムで乾燥、濾過後濃
縮して得られた残渣をシリカゲルカラムクロマトグラフ
ィー(展開溶媒;ヘキサン:酢酸エチル=15:1)で
精製して、16,17,18,19,20−ペンタノル
−15,15−ペンタメチレン−13,14−ジデヒド
ロ−PGE1 メチルエステル 11−(tert−ブ
チルジメチルシリル)−15−トリエチルシリルエーテ
ル(610mg)を得た。(2) 5-Carbomethoxypentyl zinc (II) iodide (0.92 M, tetrahydrofuran solution, 3.6 ml,
3.3 mmol) of copper (I) cyanide · lithium dichloride (1.0 M, tetrahydrofuran solution, 2.9 ml,
2.9 mmol) and stirred at the same temperature for 20 minutes. The compound (0.25) obtained in the above (1) was added to this solution at -70 ° C.
M, diethyl ether solution, 8.8 ml, 2.2 mmol
l) and chlorotrimethylsilane (0.59 ml, 3.5
mmol) and the temperature was raised to 0 ° C. over about 1 hour with stirring. A saturated aqueous ammonium chloride solution was added to the reaction solution, and the mixture was extracted with hexane. The organic layer was washed with saturated aqueous sodium hydrogen carbonate and saturated brine, dried over anhydrous magnesium sulfate, filtered and concentrated, and the residue obtained was diethyl ether (1.76 m
l) -Isopropyl alcohol (7.04 ml) was dissolved in p-toluenesulfonic acid pyridine salt (27.6 m
g, 0.11 mmol) and stirred at room temperature for 12 hours. Hexane was added to the reaction solution, and the mixture was washed with saturated aqueous sodium hydrogen carbonate and saturated brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue obtained was subjected to silica gel column chromatography (developing solvent; hexane: ethyl acetate = 15: 1). ) To give 16,17,18,19,20-pentanor-15,15-pentamethylene-13,14-didehydro-PGE 1 methyl ester 11- (tert-butyldimethylsilyl) -15-triethylsilyl ether (610 mg).
【0049】1H−NMR(CDCl3,200MHz)
δppm;0.09(s,3H),0.13(s,3
H),0.56−0.73(m,6H),0.80−
1.04(m,9H),0.90(s,9H),1.1
2−1.90(m,20H),2.09−2.38
(m,1H),2.18(dd,J=18.1,6.9
Hz,1H),2.30(t,J=7.5Hz,2
H),2.68(ddd,J=18.1,6.7,1.
3Hz,1H),2.72(dd,J=9.4,6.6
Hz,1H),3.67(s,3H),4.22−4.
37(m,1H) IR(neat);2934,2875,2857,2
234,1747,1462,1413,1375,1
290,1254,1100,1059,1005,9
05,869,838,811,779,743,67
0cm-1。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 0.09 (s, 3H), 0.13 (s, 3
H), 0.56-0.73 (m, 6H), 0.80-
1.04 (m, 9H), 0.90 (s, 9H), 1.1
2-1.90 (m, 20H), 2.09-2.38
(M, 1H), 2.18 (dd, J = 18.1, 6.9)
Hz, 1H), 2.30 (t, J = 7.5 Hz, 2
H), 2.68 (ddd, J = 18.1, 6.7, 1..
3Hz, 1H), 2.72 (dd, J = 9.4, 6.6)
Hz, 1H), 3.67 (s, 3H), 4.22-4.
37 (m, 1H) IR (neat); 2934, 2875, 2857, 2
234,1747,1462,1413,1375,1
290, 1254, 1100, 1059, 1005, 9
05,869,838,811,779,743,67
0 cm -1 .
【0050】(3)(2)で得た化合物(610mg,
1.03mmol)のメチルアルコール(10ml)溶
液を0℃に冷却し、水素化ホウ素カリウム(111m
g,2.06mmol)を加え、15分間撹拌した。水
を加え、エーテル:nーヘキサン(2:1、90ml)
にて抽出し、飽和塩化アンモニウム水溶液、飽和塩化ナ
トリウム水溶液にて洗浄した後、無水硫酸マグネシウム
で乾燥、濾過した。濾液を減圧下濃縮し、得られた残査
をシリカゲルカラムクロマトグラフィー(展開溶媒;n
−ヘキサン:AcOEt=7:1〜4:1)で精製し
て、16,17,18,19,20−ペンタノル−1
5,15−ペンタメチレン−13,14−ジデヒドロ−
PGF1α メチルエステル 11−(tert−ブチ
ルジメチルシリル)−15−トリエチルシリル エーテ
ル(221mg)、および16,17,18,19,2
0−ペンタノル−15,15−ペンタメチレン−13,
14−ジデヒドロ−PGF1β メチルエステル 11
−(tert−ブチルジメチルシリル)−15−トリエ
チルシリル エーテル(131mg)を得た。(3) The compound obtained in (2) (610 mg,
1.03 mmol) in methyl alcohol (10 ml) was cooled to 0 ° C and potassium borohydride (111 m
g, 2.06 mmol) and stirred for 15 minutes. Add water, ether: n-hexane (2: 1, 90 ml)
After washing with a saturated aqueous ammonium chloride solution and a saturated aqueous sodium chloride solution, the extract was dried over anhydrous magnesium sulfate and filtered. The filtrate is concentrated under reduced pressure, and the obtained residue is subjected to silica gel column chromatography (developing solvent; n).
-Hexane: AcOEt = 7: 1 to 4: 1) to give 16,17,18,19,20-pentanor-1.
5,15-pentamethylene-13,14-didehydro-
PGF 1 alpha methyl ester 11- (tert-butyldimethylsilyl) -15-triethylsilyl ether (221 mg), and 16,17,18,19,2
0-pentanor-15,15-pentamethylene-13,
14-didehydro-PGF 1 beta methyl ester 11
-(Tert-Butyldimethylsilyl) -15-triethylsilyl ether (131 mg) was obtained.
【0051】16,17,18,19,20−ペンタノ
ル−15,15−ペンタメチレン−13,14−ジデヒ
ドロ−PGF1α メチルエステル 11−(tert
−ブチルジメチルシリル)−15−トリエチルシリル
エーテル1 H−NMR(CDCl3,200MHz)δppm;
0.10(s,3H),0.11(s,3H),0.5
6−0.74(m,6H),0.83−1.04(m,
9H),0.89(s,9H),1.12−2.06
(m,23H),2.31(t,J=7.6Hz,2
H),2.42−2.52(m,1H),2.56
(d,J=9.4Hz,1H)3.67(s,3H),
4.04−4.19(m,1H),4.25−4.34
(m,1H) IR(neat);3467,2932,2875,2
857,2231,1743,1541,1461,1
361,1290,1254,1176,1096,1
055,1004,869,838,778,743c
m-1。[0051] 16,17,18,19,20- Pentanoru -15,15- pentamethylene 13,14-didehydro-PGF 1 alpha methyl ester 11- (tert
-Butyldimethylsilyl) -15-triethylsilyl
Ether 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.10 (s, 3H), 0.11 (s, 3H), 0.5
6-0.74 (m, 6H), 0.83-1.04 (m,
9H), 0.89 (s, 9H), 1.12 to 2.06
(M, 23H), 2.31 (t, J = 7.6 Hz, 2
H), 2.42-2.52 (m, 1H), 2.56
(D, J = 9.4 Hz, 1H) 3.67 (s, 3H),
4.04-4.19 (m, 1H), 4.25-4.34
(M, 1H) IR (neat); 3467, 2932, 2875, 2
857, 2231, 1743, 1541, 1461, 1
361, 1290, 1254, 1176, 1096, 1
055,1004,869,838,778,743c
m -1 .
【0052】16,17,18,19,20−ペンタノ
ル−15,15−ペンタメチレン−13,14−ジデヒ
ドロ−PGF1β メチルエステル 11−(tert
−ブチルジメチルシリル)−15−トリエチルシリル
エーテル1 H−NMR(CDCl3,200MHz)δppm;
0.08(s,3H),0.09(s,3H),0.5
6−0.76(m,6H),0.84−1.06(m,
9H),0.89(s,9H),1.16−1.95
(m,24H),2.25(dd,J=9.2,6.2
Hz,1H),2.31(t,J=7.5Hz,2
H),3.67(s,3H),3.89−4.08
(m,1H),4.17−4.30(m,1H) IR(neat);3435,2932,2856,2
232,1743,1461,1440,1361,1
290,1253,1176,1096,1059,1
004,925,905,869,836,811,7
78,743cm-1。[0052] 16,17,18,19,20- Pentanoru -15,15- pentamethylene 13,14-didehydro-PGF 1 beta methyl ester 11- (tert
-Butyldimethylsilyl) -15-triethylsilyl
Ether 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.08 (s, 3H), 0.09 (s, 3H), 0.5
6-0.76 (m, 6H), 0.84-1.06 (m,
9H), 0.89 (s, 9H), 1.16-1.95.
(M, 24H), 2.25 (dd, J = 9.2, 6.2)
Hz, 1H), 2.31 (t, J = 7.5 Hz, 2
H), 3.67 (s, 3H), 3.89-4.08.
(M, 1H), 4.17-4.30 (m, 1H) IR (neat); 3435, 2932, 2856, 2
232,1743,1461,1440,1361,1
290, 1253, 1176, 1096, 1059, 1
004,925,905,869,836,811,7
78,743 cm -1 .
【0053】(4)アルゴン気流下、(3)で得た 1
6,17,18,19,20−ペンタノル−15,15
−ペンタメチレン−13,14−ジデヒドロ−PGF1
α メチルエステル 11−(tert−ブチルジメチ
ルシリル)−15−トリエチルシリル エーテル(21
0mg,0.35mmol)のピリジン(1.8ml)
溶液に0℃メタンスルホニルクロリド(0.055m
l,0.71mmol)を加え、室温にて2時間撹拌し
た。この溶液にテトラ n−ブチルアンモニウムクロリ
ド(1.57g,5.65mmol)のトルエン溶液
(1.8ml)を加え45℃にて一夜撹拌した。これ
に、水を加え、n−ヘキサン抽出し、飽和食塩水にて洗
浄し、無水硫酸マグネシウムを用いて乾燥、濾過した。
濾液を濃縮し、9−デオキシ−9β−クロロ−16,1
7,18,19,20−ペンタノル−15,15−ペン
タメチレン−13,14−ジデヒドロ−PGF1α メ
チルエステル 11−(tert−ブチルジメチルシリ
ル)−15−トリエチルシリル エーテル(192m
g)を粗生成物として得た。(4) 1 obtained in (3) under a stream of argon
6,17,18,19,20-pentanor-15,15
-Pentamethylene-13,14-didehydro-PGF 1
α methyl ester 11- (tert-butyldimethylsilyl) -15-triethylsilyl ether (21
0 mg, 0.35 mmol) pyridine (1.8 ml)
Add methanesulfonyl chloride at 0 ° C (0.055m
1, 0.71 mmol) and stirred at room temperature for 2 hours. To this solution was added a toluene solution (1.8 ml) of tetra n-butylammonium chloride (1.57 g, 5.65 mmol), and the mixture was stirred at 45 ° C. overnight. Water was added thereto, extracted with n-hexane, washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered.
The filtrate was concentrated to give 9-deoxy-9β-chloro-16,1.
7,18,19,20- Pentanoru -15,15- pentamethylene 13,14-didehydro-PGF 1 alpha methyl ester 11- (tert-butyldimethylsilyl) -15-triethylsilyl ether (192m
g) was obtained as a crude product.
【0054】次いで、これをメタノール(6.3ml)
に溶かし、室温で濃塩酸(0.031ml)を加え、2
時間撹拌した。反応液を酢酸エチル:飽和重曹水に加
え、有機層を分離した。水層を酢酸エチル抽出し、有機
層を合わせて飽和重曹水で洗浄後、無水硫酸マグネシウ
ムで乾燥し、濾過した。濾液を減圧濃縮し、得られた残
査をシリカゲルカラムクロマトグラフィー(展開溶媒;
n−ヘキサン:AcOEt=3:1〜2:1)で精製し
て、標記化合物(114mg)を得た。Next, this was added to methanol (6.3 ml).
And concentrated hydrochloric acid (0.031 ml) was added at room temperature.
Stirred for hours. The reaction solution was added to ethyl acetate: saturated aqueous sodium hydrogen carbonate, and the organic layer was separated. The aqueous layer was extracted with ethyl acetate, and the organic layers were combined, washed with saturated aqueous sodium hydrogen carbonate, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was subjected to silica gel column chromatography (developing solvent;
Purification with n-hexane: AcOEt = 3: 1 to 2: 1) gave the title compound (114 mg).
【0055】1H−NMR(CDCl3,200MHz)
δppm;1.12−2.39(m,26H),2.3
2(t,J=7.4Hz,2H),3.67(s,3
H),3.88−4.03(m,3H),4.36(d
dd,J=12.8,6.4,3.5Hz,1H) IR(neat);3368,2931,2856,2
234,1739,1719,1443,1341,1
258,1175,1062,964,904,85
0,430cm-1。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 1.12-2.39 (m, 26H), 2.3
2 (t, J = 7.4 Hz, 2H), 3.67 (s, 3
H), 3.88-4.03 (m, 3H), 4.36 (d
dd, J = 12.8, 6.4, 3.5 Hz, 1H) IR (neat); 3368, 2931, 2856, 2
234, 1739, 1719, 1443, 1341, 1
258,1175,1062,964,904,85
0.430 cm -1 .
【0056】実施例2 9−デオキシ−9β−クロロ−16,17,18,1
9,20−ペンタノル−15,15−ペンタメチレン−
13,14−ジデヒドロ−PGF1α(化合物8) 実施例1で得た化合物(107mg,0.28mmo
l)のメタノール(9.3ml)−水(0.93ml)
溶液に、水酸化リチウム・1水和物(58mg,1.3
9mmol)を加え、室温で7時間撹拌した。1N塩酸
水溶液を加え中和の後、濃縮した。残査に酢酸エチル
(20ml)を加え、0.1N塩酸を加えて酸性とした
後、硫酸アンモニウムにて塩析した後有機層を分取し
た。有機層をシリカゲルカラムクロマトグラフィー(展
開溶媒;n−ヘキサン:AcOEt=1:1〜1:2)
で精製して、標記化合物(65.5mg)を得た。Example 2 9-Deoxy-9β-chloro-16,17,18,1
9,20-pentanor-15,15-pentamethylene-
13,14-didehydro-PGF 1 alpha (Compound 8) Compound obtained in Example 1 (107mg, 0.28mmo
l) Methanol (9.3 ml) -water (0.93 ml)
Lithium hydroxide monohydrate (58 mg, 1.3
9 mmol) and stirred at room temperature for 7 hours. After neutralization by adding a 1N aqueous hydrochloric acid solution, the mixture was concentrated. Ethyl acetate (20 ml) was added to the residue, and the mixture was acidified by adding 0.1 N hydrochloric acid. After salting out with ammonium sulfate, the organic layer was separated. The organic layer is subjected to silica gel column chromatography (developing solvent; n-hexane: AcOEt = 1: 1 to 1: 2).
The title compound (65.5 mg) was obtained.
【0057】1H−NMR(CDCl3,300MHz)
δppm;1.14−3.64(m,27H),2.3
6(t,J=7.3Hz,2H),3.90−4.00
(m,1H),4.31−4.40(m,1H) IR(neat);3350,2933,2853,2
235,1708,1445,1411,1341,1
283,1258,1181,1135,1060,9
63,904,850,805,726cm-1。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.14-3.64 (m, 27H), 2.3
6 (t, J = 7.3 Hz, 2H), 3.90-4.00
(M, 1H), 4.31-4.40 (m, 1H) IR (neat); 3350, 2933, 2853, 2
235,1708,1445,1411,1341,1
283,1258,1181,1135,1060,9
63,904,850,805,726 cm- 1 .
【0058】実施例3 (2E)−9−デオキシ−9β−クロロ−16,17,
18,19,20−ペンタノル−15,15−ヘキサメ
チレン−2,3,13,14−テトラデヒドロ−PGF
1α メチルエステル(化合物19) (1)実施例1(1)において、1−エチニル−1−ト
リエチルシロキシシクロヘキサンの代わりに1−エチニ
ル−1−トリエチルシロキシシクロヘプタンを用い、実
施例(1)と実質的に同様にして、(3R,4R)−2
−メチレン−3−[3,3−ヘキサメチレン−3−(ト
リエチルシロキシ)プロパ−1−イニル]−4−(te
rt−ブチルジメチルシロキシ)シクロペンタン−1−
オンを得た。Example 3 (2E) -9-Deoxy-9β-chloro-16,17,
18,19,20-pentanor-15,15-hexamethylene-2,3,13,14-tetradehydro-PGF
In 1 alpha methyl ester (Compound 19) (1) Example 1 (1), 1-ethynyl-1-using 1-ethynyl-1-triethylsiloxy cycloheptane instead of triethylsiloxy cyclohexane, Example (1) Substantially in the same manner, (3R, 4R) -2
-Methylene-3- [3,3-hexamethylene-3- (triethylsiloxy) prop-1-ynyl] -4- (te
rt-butyldimethylsiloxy) cyclopentane-1-
Got on.
【0059】1H−NMR(CDCl3,200MHz)
δppm;0.10(s,3H),0.14(s,3
H),0.55−0.72(m,6H),0.84−
1.02(m,9H),0.90(s,9H),1.2
0−2.26(m,12H),2.33(dd,J=1
8.0,7.0Hz,1H),2.73(dd,J=1
8.0,6.4Hz,1H),3.55(t,J=6.
6,2.6Hz,1H),4.23−4.37(m,1
H),5.56(dd,J=2.6,0.7Hz,1
H),6.16(dd,J=2.9,0.7Hz,1
H) IR(neat);2932,2876,2858,2
208,1713,1620,1461,1412,1
362,1286,1255,1188,1088,1
006,938,837,779,744cm-1。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 0.10 (s, 3H), 0.14 (s, 3
H), 0.55-0.72 (m, 6H), 0.84-
1.02 (m, 9H), 0.90 (s, 9H), 1.2
0-2.26 (m, 12H), 2.33 (dd, J = 1
8.0, 7.0 Hz, 1H), 2.73 (dd, J = 1
8.0, 6.4 Hz, 1H), 3.55 (t, J = 6.
6, 2.6 Hz, 1H), 4.23-4.37 (m, 1
H), 5.56 (dd, J = 2.6, 0.7 Hz, 1
H), 6.16 (dd, J = 2.9, 0.7 Hz, 1
H) IR (neat); 2932, 2876, 2858, 2
208, 1713, 1620, 1461, 1412, 1
362, 1286, 1255, 1188, 1088, 1
006, 938, 837, 779, 744 cm -1 .
【0060】(2)上記(1)で得た化合物を用い、実
施例1(2)の5−カルボメトキシペンチル亜鉛(II)
ヨージドの代わりに(E)−5−カルボメトキシ−4−
ペンテニル亜鉛(II)ヨージドを用い、実施例1(2)
と実質的に同様にして、(2E)−16,17,18,
19,20−ペンタノル−15,15−ヘキサメチレン
−2,3,13,14−テトラデヒドロ−PGE1 メ
チルエステル 11−tert−ブチルジメチルシリル
−15−トリエチルシリル エーテルを得た。(2) Using the compound obtained in (1) above, 5-carbomethoxypentyl zinc (II) of Example 1 (2)
(E) -5-Carbomethoxy-4- instead of iodide
Example 1 (2) using pentenylzinc (II) iodide
And (2E) -16, 17, 18,
19,20-Pentanol-15,15-hexamethylene-2,3,13,14-tetradehydro-PGE 1 methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether was obtained.
【0061】1H−NMR(CDCl3,200MHz)
δppm;0.09(s,3H),0.13(s,3
H),0.55−0.75(m,6H),0.85−
1.05(m,9H),0.90(s,9H),1.1
9−2.46(m,22H),2.60−2.77
(m,1H),2.70(dd,J=9.6,6.7H
z,1H),3.73(s,3H),4.22−4.3
7(m,1H),5.82(dt,J=15.6,1.
5Hz,1H),6.96(dt,J=15.6,6.
9Hz,1H) IR(neat);2933,2874,2858,2
230,1749,1728,1659,1460,1
436,1412,1375,1361,1259,1
234,1195,1121,1066,1005,9
40,837,778,743,670cm-1。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 0.09 (s, 3H), 0.13 (s, 3
H), 0.55-0.75 (m, 6H), 0.85-
1.05 (m, 9H), 0.90 (s, 9H), 1.1
9-2.46 (m, 22H), 2.60-2.77
(M, 1H), 2.70 (dd, J = 9.6, 6.7H
z, 1H), 3.73 (s, 3H), 4.22-4.3.
7 (m, 1H), 5.82 (dt, J = 15.6, 1..
5 Hz, 1 H), 6.96 (dt, J = 15.6, 6.
9Hz, 1H) IR (neat); 2933, 2874, 2858, 2
230, 1749, 1728, 1659, 1460, 1
436, 1412, 1375, 1361, 1259, 1
234, 1195, 1121, 1066, 1005, 9
40,837,778,743,670 cm -1 .
【0062】(3)上記(2)で得た化合物を用い、実
施例1(3)と実質的に同様にして、(2E)−16,
17,18,19,20−ペンタノル−15,15−ヘ
キサメチレン−2,3,13,14−テトラデヒドロ−
PGF1α メチルエステル11−tert−ブチルジ
メチルシリル−15−トリエチルシリル エーテルおよ
び(2E)−16,17,18,19,20−ペンタノ
ル−15,15−ヘキサメチレン−2,3,13,14
−テトラデヒドロ−PGF1β メチルエステル 11
−tert−ブチルジメチルシリル−15−トリエチル
シリル エーテルを得た。(3) Using the compound obtained in (2) above, (2E) -16, substantially in the same manner as in Example 1 (3)
17,18,19,20-pentanor-15,15-hexamethylene-2,3,13,14-tetradehydro-
PGF 1 alpha methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether and (2E) -16,17,18,19,20- Pentanoru -15,15- hexamethylene -2,3,13,14
-Tetradehydro-PGF 1 β methyl ester 11
-Tert-Butyldimethylsilyl-15-triethylsilyl ether was obtained.
【0063】(2E)−16,17,18,19,20
−ペンタノル−15,15−ヘキサメチレン−2,3,
13,14−テトラデヒドロ−PGF1α メチルエス
テル11−tert−ブチルジメチルシリル−15−ト
リエチルシリル エーテル1 H−NMR(CDCl3,200MHz)δppm;
0.10(s,3H),0.12(s,3H),0.5
6−0.73(m,6H),0.86−1.02(m,
9H),0.89(s,9H),1.18−2.06
(m,21H),2.15−2.31(m,2H),
2.42−2.52(m,1H),2.58(d,J=
9.7Hz,1H),3.73(s,3H),4.06
−4.20(m,1H),4.26−4.35(m,1
H),5.83(dt,J=15.6,1.5Hz,1
H),6.98(dt,J=15.6,7.0Hz,1
H) IR(neat);3468,2930,2874,2
857,2229,1728,1711,1656,1
461,1436,1361,1256,1196,1
065,1004,837,777,743cm-1。(2E) -16, 17, 18, 19, 20
-Pentanor-15,15-hexamethylene-2,3
13,14 Tetoradehidoro-PGF 1 alpha methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether 1 H-NMR (CDCl 3, 200MHz) δppm;
0.10 (s, 3H), 0.12 (s, 3H), 0.5
6-0.73 (m, 6H), 0.86-1.02 (m,
9H), 0.89 (s, 9H), 1.18-2.06
(M, 21H), 2.15-2.31 (m, 2H),
2.42-2.52 (m, 1H), 2.58 (d, J =
9.7 Hz, 1H), 3.73 (s, 3H), 4.06
-4.20 (m, 1H), 4.26-4.35 (m, 1
H), 5.83 (dt, J = 15.6, 1.5 Hz, 1
H), 6.98 (dt, J = 15.6, 7.0 Hz, 1
H) IR (neat); 3468,2930,2874,2
857, 2229, 1728, 1711, 1656, 1
461, 1436, 1361, 1256, 1196, 1
065, 1004, 837, 777, 743 cm -1 .
【0064】(2E)−16,17,18,19,20
−ペンタノル−15,15−ヘキサメチレン−2,3,
13,14−テトラデヒドロ−PGF1β メチルエス
テル11−tert−ブチルジメチルシリル−15−ト
リエチルシリル エーテル1 H−NMR(CDCl3,200MHz)δppm;
0.08(s,3H),0.09(s,3H),0.5
6−0.73(m,6H),0.82−1.03(m,
9H),0.89(s,9H),1.18−1.98
(m,22H),2.14−2.31(m,2H),
2.24(dd,J=9.1,6.0Hz,1H),
3.73(s,3H),3.90−4.06(m,1
H),4.17−4.30(m,1H),5.83(d
t,J=15.8,1.4Hz,1H),6.98(d
t,J=15.8,6.9Hz,1H) IR(neat);3436,2930,2875,2
857,2224,1728,1708,1657,1
461,1437,1361,1256,1195,1
123,1065,1005,836,777,74
3,670,418cm-1。(2E) -16, 17, 18, 19, 20
-Pentanor-15,15-hexamethylene-2,3
13,14-tetradehydro-PGF 1 β methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.08 (s, 3H), 0.09 (s, 3H), 0.5
6-0.73 (m, 6H), 0.82-1.03 (m,
9H), 0.89 (s, 9H), 1.18-1.98
(M, 22H), 2.14-2.31 (m, 2H),
2.24 (dd, J = 9.1, 6.0 Hz, 1H),
3.73 (s, 3H), 3.90-4.06 (m, 1
H), 4.17-4.30 (m, 1H), 5.83 (d
t, J = 15.8, 1.4 Hz, 1H), 6.98 (d
t, J = 15.8, 6.9 Hz, 1H) IR (neat); 3436, 2930, 2875, 2
857, 2224, 1728, 1708, 1657, 1
461, 1437, 1361, 1256, 1195, 1
123,1065,1005,836,777,74
3,670,418 cm -1 .
【0065】(4)上記(3)で得た(2E)−16,
17,18,19,20−ペンタノル−15,15−ヘ
キサメチレン−2,3,13,14−テトラデヒドロ−
PGF 1α メチルエステル 11−tert−ブチル
ジメチルシリル−15−トリエチルシリル エーテルを
用い、実施例1(4)と実質的に同様にして、標記化合
物を得た。(4) (2E) -16 obtained in the above (3)
17,18,19,20-pentanor-15,15-f
Xamethylene-2,3,13,14-tetradehydro-
PGF 1α-methyl ester 11-tert-butyl
Dimethylsilyl-15-triethylsilyl ether
The compound was used in substantially the same manner as in Example 1 (4).
I got something.
【0066】1H−NMR(CDCl3,300MHz)
δppm;0.83−2.33(m,26H),3.7
3(s,3H),3.89−4.00(m,1H),
4.31−4.40(m,1H),5.84(dt,J
=15.7,1.5Hz,1H),6.98(dt,J
=15.7,7.0Hz,1H) IR(neat);3400,2930,2857,2
235,1724,1707,1656,1460,1
438,1283,1203,1027,980,91
2,858,798,719cm-1。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 0.83-2.33 (m, 26H), 3.7
3 (s, 3H), 3.89-4.00 (m, 1H),
4.31-4.40 (m, 1H), 5.84 (dt, J
= 15.7, 1.5 Hz, 1H), 6.98 (dt, J
= 15.7, 7.0 Hz, 1H) IR (neat); 3400, 2930, 2857, 2
235, 1724, 1707, 1656, 1460, 1
438,1283,1203,1027,980,91
2,858,798,719 cm -1 .
【0067】実施例4 (2E)−9−デオキシ−9β−クロロ−16,17,
18,19,20−ペンタノル−15,15−ヘキサメ
チレン−2,3,13,14−テトラデヒドロ−PGF
1α(化合物20) リパーゼPS(0.97g)の水(13ml)懸濁液
に、実施例3で得た化合物(34mg,0.0857m
mol)のアセトン(1.76ml)溶液、リン酸緩衝
液(pH=7.0,0.2M,0.945ml)および
水(5.7ml)を加え30℃で一夜撹拌した。反応液
を濾過し、濾液を0.5N塩酸にて酸性とした後、硫酸
アンモニウムにて塩析し、酢酸エチルで抽出した。有機
層を飽和食塩水で洗浄、無水硫酸マグネシウムで乾燥、
濾過した。濾液を減圧濃縮し、得られたを残査シリカゲ
ルカラムクロマトグラフィー(展開溶媒;ヘキサン:酢
酸エチル=1:2〜1:5)で精製し、標記化合物(2
9mg)を得た。Example 4 (2E) -9-Deoxy-9β-chloro-16,17,
18,19,20-pentanor-15,15-hexamethylene-2,3,13,14-tetradehydro-PGF
1 α (Compound 20) The compound obtained in Example 3 (34 mg, 0.0857 m) was added to a suspension of lipase PS (0.97 g) in water (13 ml).
mol) in acetone (1.76 ml), a phosphate buffer (pH = 7.0, 0.2 M, 0.945 ml) and water (5.7 ml), and the mixture was stirred at 30 ° C. overnight. The reaction solution was filtered, the filtrate was acidified with 0.5N hydrochloric acid, salted out with ammonium sulfate, and extracted with ethyl acetate. The organic layer was washed with saturated saline and dried over anhydrous magnesium sulfate,
Filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (eluent: hexane: ethyl acetate = 1: 2-1: 5) to give the title compound (2
9 mg).
【0068】1H−NMR(CDCl3,200MHz)
δppm;0.80−2.38(m,24H),2.5
0−3.80(br,3H),3.88−4.02
(m,1H),4.29−4.42(m,1H),5.
85(dt,J=15.6,1.4Hz,1H),7.
08(dt,J=15.8,6.9Hz,1H) IR(neat);3367,2930,2858,2
677,2235,1696,1652,1460,1
445,1418,1283,1085,1023,9
81,911,757,668cm-1。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 0.80-2.38 (m, 24H), 2.5
0-3.80 (br, 3H), 3.88-4.02
(M, 1H), 4.29-4.42 (m, 1H), 5.
85 (dt, J = 15.6, 1.4 Hz, 1H), 7.
08 (dt, J = 15.8, 6.9 Hz, 1H) IR (neat); 3367, 2930, 2858, 2
677, 2235, 1696, 1652, 1460, 1
445, 1418, 1283, 1085, 1023, 9
81,911,757,668 cm -1 .
【0069】実施例5 (2E)−9−デオキシ−9β−クロロ−16,17,
18,19,20−ペンタノル−15,15−ペンタメ
チレン−2,3,13,14−テトラデヒドロ−PGF
1α メチルエステル(化合物17) (1)実施例1(2)において、5−カルボメトキシペ
ンチル亜鉛(II)ヨージドの代わりに、(E)−5−カ
ルボメトキシ−4−ペンテニル亜鉛(II)ヨージドを用
い、実施例1(2)と実質的に同様にして、(2E)−
16,17,18,19,20−ペンタノル−15,1
5−ペンタメチレン−2,3,13,14−テトラデヒ
ドロ−PGE1 メチルエステル 11−tert−ブ
チルジメチルシリル−15−トリエチルシリル エーテ
ルを得た。Example 5 (2E) -9-Deoxy-9β-chloro-16,17,
18,19,20-pentanor-15,15-pentamethylene-2,3,13,14-tetradehydro-PGF
In 1 alpha methyl ester (Compound 17) (1) Example 1 (2), 5-carbonitrile in place of methoxy pentyl zinc (II) iodide, (E)-5-carbomethoxy-4-pentenyl zinc (II) iodide And (2E) − in substantially the same manner as in Example 1 (2).
16,17,18,19,20-Pentanol-15,1
5-pentamethylene-2,3,13,14-tetradehydro-PGE 1 methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether was obtained.
【0070】1H−NMR(CDCl3,200MHz)
δppm;0.09(s,3H),0.13(s,3
H),0.57−0.72(m,6H),0.84−
1.02(m,9H),0.90(s,9H),1.1
5−1.88(m,16H),2.09−2.30
(m,3H),2.18(dd,J=18.2,6.8
Hz,1H),2.61−2.77(m,1H),2.
71(dd,J=9.3,6.7Hz,1H),3.7
3(s,3H),4.22−4.36(m,1H),
5.82(dt,J=15.6,1.5Hz,1H),
6.96(dt,J=15.6,6.9z,1H) IR(neat);2934,2875,2858,2
233,1748,1728,1658,1462,1
437,1412,1376,1257,1197,1
177,1100,1056,1004,869,83
8,811,779,743,670cm-1。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 0.09 (s, 3H), 0.13 (s, 3
H), 0.57-0.72 (m, 6H), 0.84-
1.02 (m, 9H), 0.90 (s, 9H), 1.1
5-1.88 (m, 16H), 2.09-2.30
(M, 3H), 2.18 (dd, J = 18.2, 6.8
Hz, 1H), 2.61-2.77 (m, 1H), 2.
71 (dd, J = 9.3, 6.7 Hz, 1H), 3.7
3 (s, 3H), 4.22-4.36 (m, 1H),
5.82 (dt, J = 15.6, 1.5 Hz, 1H),
6.96 (dt, J = 15.6, 6.9z, 1H) IR (neat); 2934, 2875, 2858, 2
233,1748,1728,1658,1462,1
437, 1412, 1376, 1257, 1197, 1
177, 1100, 1056, 1004, 869, 83
8,811,779,743,670 cm -1 .
【0071】(2)上記(1)で得た化合物を用い、実
施例1(3)と実質的に同様にして、(2E)−16,
17,18,19,20−ペンタノル−15,15−ペ
ンタメチレン−2,3,13,14−テトラデヒドロ−
PGF1α メチルエステル11−tert−ブチルジ
メチルシリル−15−トリエチルシリル エーテルおよ
び(2E)−16,17,18,19,20−ペンタノ
ル−15,15−ペンタメチレン−2,3,13,14
−テトラデヒドロ−PGF1β メチルエステル 11
−tert−ブチルジメチルシリル−15−トリエチル
シリル エーテルを得た。(2) Using the compound obtained in (1) above, (2E) -16, substantially as in Example 1 (3)
17,18,19,20-pentanor-15,15-pentamethylene-2,3,13,14-tetradehydro-
PGF 1 alpha methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether and (2E) -16,17,18,19,20- Pentanoru -15,15- pentamethylene -2,3,13,14
-Tetradehydro-PGF 1 β methyl ester 11
-Tert-Butyldimethylsilyl-15-triethylsilyl ether was obtained.
【0072】(2E)−16,17,18,19,20
−ペンタノル−15,15−ペンタメチレン−2,3,
13,14−テトラデヒドロ−PGF1α メチルエス
テル11−tert−ブチルジメチルシリル−15−ト
リエチルシリル エーテル1 H−NMR(CDCl3,200MHz)δppm;
0.10(s,3H),0.12(s,3H),0.5
6−0.74(m,6H),0.86−1.06(m,
9H),0.89(s,9H),1.16−2.34
(m,21H),2.42−2.52(m,1H),
2.58(d,J=9.7Hz,1H),3.73
(s,3H),4.06−4.20(m,1H),4.
24−4.35(m,1H),5.82(dt,J=1
5.7,1.6Hz,1H),6.98(dt,J=1
5.7,7.0Hz,1H) IR(neat);3467,2932,2857,2
230,1729,1657,1462,1438,1
384,1255,1178,1096,1054,1
004,869,837,778,743,408cm
-1。(2E) -16, 17, 18, 19, 20
-Pentanor-15,15-pentamethylene-2,3
13,14 Tetoradehidoro-PGF 1 alpha methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether 1 H-NMR (CDCl 3, 200MHz) δppm;
0.10 (s, 3H), 0.12 (s, 3H), 0.5
6-0.74 (m, 6H), 0.86-1.06 (m,
9H), 0.89 (s, 9H), 1.16-2.34.
(M, 21H), 2.42-2.52 (m, 1H),
2.58 (d, J = 9.7 Hz, 1H), 3.73
(S, 3H), 4.06-4.20 (m, 1H), 4.
24-4.35 (m, 1H), 5.82 (dt, J = 1
5.7, 1.6 Hz, 1H), 6.98 (dt, J = 1
5.7, 7.0 Hz, 1H) IR (neat); 3467, 2932, 2857, 2
230, 1729, 1657, 1462, 1438, 1
384, 1255, 1178, 1096, 1054, 1
004,869,837,778,743,408cm
-1 .
【0073】(2E)−16,17,18,19,20
−ペンタノル−15,15−ペンタメチレン−2,3,
13,14−テトラデヒドロ−PGF1β メチルエス
テル11−tert−ブチルジメチルシリル−15−ト
リエチルシリル エーテル1 H−NMR(CDCl3,200MHz)δppm;
0.08(s,3H),0.09(s,3H),0.5
8−0.74(m,6H),0.83−1.03(m,
9H),0.89(s,9H),1.14−1.94
(m,20H),2.14−2.32(m,2H),
2.25(dd,J=9.2,5.9Hz,1H),
3.73(s,3H),3.89−4.08(m,1
H),4.16−4.30(m,1H),5.83(d
t,J=15.6,1.5Hz,1H),6.98(d
t,J=15.6,6.9Hz,1H) IR(neat);3435,2932,2876,2
857,2231,1729,1708,1657,1
461,1438,1290,1255,1179,1
096,1058,1005,924,905,86
8,837,837,811,778,743cm-1。(2E) -16, 17, 18, 19, 20
-Pentanor-15,15-pentamethylene-2,3
13,14-tetradehydro-PGF 1 β methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.08 (s, 3H), 0.09 (s, 3H), 0.5
8-0.74 (m, 6H), 0.83-1.03 (m,
9H), 0.89 (s, 9H), 1.14 to 1.94.
(M, 20H), 2.14.2.32 (m, 2H),
2.25 (dd, J = 9.2, 5.9 Hz, 1H),
3.73 (s, 3H), 3.89-4.08 (m, 1
H), 4.16-4.30 (m, 1H), 5.83 (d
t, J = 15.6, 1.5 Hz, 1H), 6.98 (d
t, J = 15.6, 6.9 Hz, 1H) IR (neat); 3435, 2932, 2876, 2
857, 2231, 1729, 1708, 1657, 1
461, 1438, 1290, 1255, 1179, 1
096,1058,1005,924,905,86
8,837,837,811,778,743 cm -1 .
【0074】(3)上記(2)で得た(2E)−16,
17,18,19,20−ペンタノル−15,15−ペ
ンタメチレン−2,3,13,14−テトラデヒドロ−
PGF1α メチルエステル 11−tert−ブチル
ジメチルシリル−15−トリエチルシリル エーテルを
用い、実施例1(4)と実質的に同様にして、標記化合
物を得た。(3) (2E) -16 obtained in the above (2)
17,18,19,20-pentanor-15,15-pentamethylene-2,3,13,14-tetradehydro-
With PGF 1 alpha methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether, in substantially the same manner as in Example 1 (4), to give the title compound.
【0075】1H−NMR(CDCl3,200MHz)
δppm;1.12−2.37(m,24H),3.7
3(s,3H),3.88−4.02(m,1H),
4.29−4.43(m,1H),5.84(dt,J
=15.7,1.5Hz,1H),6.98(dt,J
=15.7,7.0Hz,1H) IR(neat);3400,2933,2857,2
235,1724,1707,1656,1438,1
315,1284,1202,1179,1061,9
64,904,849,718,499,423c
m-1。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 1.12-2.37 (m, 24H), 3.7
3 (s, 3H), 3.88-4.02 (m, 1H),
4.29-4.43 (m, 1H), 5.84 (dt, J
= 15.7, 1.5 Hz, 1H), 6.98 (dt, J
= 15.7, 7.0 Hz, 1H) IR (neat); 3400, 2933, 2857, 2
235, 1724, 1707, 1656, 1438, 1
315, 1284, 1202, 1179, 1061, 9
64,904,849,718,499,423c
m -1 .
【0076】実施例6 (2E)−9−デオキシ−9β−クロロ−16,17,
18,19,20−ペンタノル−15,15−ペンタメ
チレン−2,3,13,14−テトラデヒドロ−PGF
1α(化合物18) 実施例5で得た化合物を用い、実施例4と実質的に同様
にして、標記化合物を得た。Example 6 (2E) -9-Deoxy-9β-chloro-16,17,
18,19,20-pentanor-15,15-pentamethylene-2,3,13,14-tetradehydro-PGF
Using 1 alpha (Compound 18) Compound obtained in Example 5, in substantially the same manner as in Example 4 to give the title compound.
【0077】1H−NMR(CDCl3,300MHz)
δppm;1.08−3.80(m,25H),3.8
9−4.00(m,1H),4.30−4.40(m,
1H),5.85(dt,J=15.6,1.4Hz,
1H),7.07(dt,J=15.6,7.0Hz,
1H) IR(neat);3367,2933,2857,2
234,1696,1653,1445,1419,1
284,1060,980,963,904,850,
757,668,533,422cm-1。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.08-3.80 (m, 25H), 3.8
9-4.00 (m, 1H), 4.30-4.40 (m, 1H)
1H), 5.85 (dt, J = 15.6, 1.4 Hz,
1H), 7.07 (dt, J = 15.6, 7.0 Hz,
1H) IR (neat); 3367, 2933, 2857, 2
234,1696,1653,1445,1419,1
284, 1060, 980, 963, 904, 850,
757,668,533,422 cm -1 .
【0078】実施例7 (2E)−9−デオキシ−9β−クロロ−16,17,
18,19,20−ペンタノル−15,15−テトラメ
チレン−2,3,13,14−テトラデヒドロ−PGF
1α メチルエステル(化合物15) (1)実施例1(1)において、1−エチニル−1−ト
リエチルシロキシシクロヘキサンの代わりに1−エチニ
ル−1−トリエチルシロキシシクロペンタンを用い、実
施例1(1)と実質的に同様にして、(3R,4R)−
2−メチレン−3−[3,3−テトラメチレン−3−
(トリエチルシロキシ)プロパ−1−イニル]−4−
(tert−ブチルジメチルシロキシ)シクロペンタン
−1−オンを得た。Example 7 (2E) -9-Deoxy-9β-chloro-16,17,
18,19,20-pentanor-15,15-tetramethylene-2,3,13,14-tetradehydro-PGF
1 alpha methyl ester (Compound 15) (1) In Example 1 (1), 1-ethynyl-1-using 1-ethynyl-1-triethylsiloxy cyclopentane instead of triethylsiloxy cyclohexane, Example 1 (1) And (3R, 4R)-
2-methylene-3- [3,3-tetramethylene-3-
(Triethylsiloxy) prop-1-ynyl] -4-
(Tert-Butyldimethylsiloxy) cyclopentan-1-one was obtained.
【0079】1H−NMR(CDCl3,200MHz)
δppm;0.11(s,3H),0.14(s,3
H),0.54−0.72(m,6H),0.80−
1.02(m,9H),0.90(s,9H),1.6
0−1.90(m,8H),2.33(dd,J=1
7.9,7.4Hz,1H),2.72(dd,J=1
7.9,6.5Hz,1H),3.48−3.59
(m,1H),4.20−4.35(m,1H),5.
56(dd,J=2.6,0.7Hz,1H),6.1
6(dd,J=3.1,0.7Hz,1H) IR(neat);3401,2955,2876,2
210,1737,1714,1621,1463,1
412,1362,1255,1187,1109,1
063,1007,941,889,837,779,
744,671cm-1。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 0.11 (s, 3H), 0.14 (s, 3
H), 0.54-0.72 (m, 6H), 0.80-
1.02 (m, 9H), 0.90 (s, 9H), 1.6
0-1.90 (m, 8H), 2.33 (dd, J = 1
7.9, 7.4 Hz, 1H), 2.72 (dd, J = 1
7.9, 6.5 Hz, 1H), 3.48-3.59
(M, 1H), 4.20-4.35 (m, 1H), 5.
56 (dd, J = 2.6, 0.7 Hz, 1H), 6.1
6 (dd, J = 3.1, 0.7 Hz, 1H) IR (neat); 3401, 2955, 2876, 2
210, 1737, 1714, 1621, 1463, 1
412, 1362, 1255, 1187, 1109, 1
063, 1007, 941, 889, 837, 779,
744,671 cm -1 .
【0080】(2)上記(1)で得た化合物を用い、実
施例3(2)と実質的に同様にして、(2E)−16,
17,18,19,20−ペンタノル−15,15−テ
トラメチレン−2,3,13,14−テトラデヒドロ−
PGE1 メチルエステル 11−tert−ブチルジ
メチルシリル−15−トリエチルシリル エーテルを得
た。(2) Using the compound obtained in (1) above, (2E) -16, substantially as in Example 3 (2)
17,18,19,20-pentanor-15,15-tetramethylene-2,3,13,14-tetradehydro-
PGE 1 methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether was obtained.
【0081】1H−NMR(CDCl3,200MHz)
δppm;0.10(s,3H),0.13(s,3
H),0.56−0.70(m,6H),0.90
(s,9H),0.84−1.02(m,9H),1.
20−1.90(m,14H),2.09−2.28
(m,4H),2.60−2.75(m,2H),3.
73(s,3H),4.21−4.35(m,1H),
5.82(dt,J=15.6,1.5Hz,1H),
6.96(dt,J=15.6,7.0Hz,1H) IR(neat);2952,2874,2234,1
749,1727,1659,1462,1435,1
376,1259,1197,1118,1058,1
007,876,837,778,743,430cm
-1。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 0.10 (s, 3H), 0.13 (s, 3
H), 0.56-0.70 (m, 6H), 0.90
(S, 9H), 0.84-1.02 (m, 9H), 1.
20-1.90 (m, 14H), 2.09-2.28
(M, 4H), 2.60-2.75 (m, 2H), 3.
73 (s, 3H), 4.21-4.35 (m, 1H),
5.82 (dt, J = 15.6, 1.5 Hz, 1H),
6.96 (dt, J = 15.6, 7.0 Hz, 1H) IR (neat); 2952, 2874, 2234, 1
749, 1727, 1659, 1462, 1435, 1
376, 1259, 1197, 1118, 1058, 1
007,876,837,778,743,430cm
-1 .
【0082】(3)上記(2)で得た化合物を用い、実
施例1(3)と実質的に同様にして、(2E)−16,
17,18,19,20−ペンタノル−15,15−テ
トラメチレン−2,3,13,14−テトラデヒドロ−
PGF1α メチルエステル11−tert−ブチルジ
メチルシリル−15−トリエチルシリル エーテルおよ
び(2E)−16,17,18,19,20−ペンタノ
ル−15,15−テトラメチレン−2,3,13,14
−テトラデヒドロ−PGF1β メチルエステル 11
−tert−ブチルジメチルシリル−15−トリエチル
シリル エーテルを得た。(3) Using the compound obtained in (2) above, (2E) -16, substantially in the same manner as in Example 1 (3)
17,18,19,20-pentanor-15,15-tetramethylene-2,3,13,14-tetradehydro-
PGF 1 alpha methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether and (2E) -16,17,18,19,20- Pentanoru -15,15- tetramethylene -2,3,13,14
-Tetradehydro-PGF 1 β methyl ester 11
-Tert-Butyldimethylsilyl-15-triethylsilyl ether was obtained.
【0083】(2E)−16,17,18,19,20
−ペンタノル−15,15−テトラメチレン−2,3,
13,14−テトラデヒドロ−PGF1α メチルエス
テル11−tert−ブチルジメチルシリル−15−ト
リエチルシリル エーテル1 H−NMR(CDCl3,200MHz)δppm;
0.10(s,3H),0.11(s,3H),0.5
6−0.74(m,6H),0.86−1.04(m,
9H),0.89(s,9H),1.32−2.05
(m,17H),2.17−2.30(m,2H),
2.41−2.56(m,2H),3.73(s,3
H),4.06−4.20(m,1H),4.25−
4.32(m,1H),5.83(dt,J=15.
7,1.5Hz,1H),6.98(dt,J=15.
7,6.9Hz,1H) IR(neat);3467,2952,2933,2
874,2857,2230,1728,1656,1
462,1436,1413,1384,1361,1
323,1256,1199,1112,1055,1
006,977,881,837,777,743cm
-1。(2E) -16, 17, 18, 19, 20
-Pentanor-15,15-tetramethylene-2,3
13,14 Tetoradehidoro-PGF 1 alpha methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether 1 H-NMR (CDCl 3, 200MHz) δppm;
0.10 (s, 3H), 0.11 (s, 3H), 0.5
6-0.74 (m, 6H), 0.86-1.04 (m,
9H), 0.89 (s, 9H), 1.32-2.05
(M, 17H), 2.17-2.30 (m, 2H),
2.41-2.56 (m, 2H), 3.73 (s, 3
H), 4.06-4.20 (m, 1H), 4.25-
4.32 (m, 1H), 5.83 (dt, J = 15.
7, 1.5 Hz, 1 H), 6.98 (dt, J = 15.
7,6.9 Hz, 1H) IR (neat); 3467,2952,2933,2
874, 2857, 2230, 1728, 1656, 1
462, 1436, 1413, 1384, 1361, 1
323, 1256, 1199, 1112, 1055, 1
006,977,881,837,777,743cm
-1 .
【0084】(2E)−16,17,18,19,20
−ペンタノル−15,15−テトラメチレン−2,3,
13,14−テトラデヒドロ−PGF1β メチルエス
テル11−tert−ブチルジメチルシリル−15−ト
リエチルシリル エーテル1 H−NMR(CDCl3,200MHz)δppm;
0.08(s,3H),0.09(s,3H),0.5
7−0.74(m,6H),0.84−1.03(m,
9H),0.89(s,9H),1.40−2.00
(m,18H),2.16−2.30(m,2H),
2.22(dd,J=9.3,6.3Hz,1H),
3.73(s,3H),3.90−4.06(m,1
H),4.16−4.30(m,1H),5.83(d
t,J=15.6,1.5Hz,1H),6.98(d
t,J=15.6,6.9Hz,1H) IR(neat);3435,2952,2930,2
874,2857,2234,1728,1708,1
657,1462,1437,1252,1201,1
116,1058,1006,836,777,743
cm-1。(2E) -16, 17, 18, 19, 20
-Pentanor-15,15-tetramethylene-2,3
13,14-tetradehydro-PGF 1 β methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.08 (s, 3H), 0.09 (s, 3H), 0.5
7-0.74 (m, 6H), 0.84-1.03 (m,
9H), 0.89 (s, 9H), 1.40-2.00
(M, 18H), 2.16-2.30 (m, 2H),
2.22 (dd, J = 9.3, 6.3 Hz, 1H),
3.73 (s, 3H), 3.90-4.06 (m, 1
H), 4.16-4.30 (m, 1H), 5.83 (d
t, J = 15.6, 1.5 Hz, 1H), 6.98 (d
t, J = 15.6, 6.9 Hz, 1H) IR (neat); 3435, 2952, 2930, 2
874, 2857, 2234, 1728, 1708, 1
657, 1462, 1437, 1252, 1201, 1
116,1058,1006,836,777,743
cm -1 .
【0085】(4)上記で(3)で得た(2E)−1
6,17,18,19,20−ペンタノル−15,15
−テトラメチレン−2,3,13,14−テトラデヒド
ロ−PGF1α メチルエステル 11−tert−ブ
チルジメチルシリル−15−トリエチルシリル エーテ
ルを用い、実施例1(4)と実質的に同様にして、標記
化合物を得た。(4) (2E) -1 obtained in (3) above
6,17,18,19,20-pentanor-15,15
- using a tetramethylene -2,3,13,14- Tetoradehidoro-PGF 1 alpha methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether, in substantially the same manner as in Example 1 (4), The title compound was obtained.
【0086】1H−NMR(CDCl3,300MHz)
δppm;1.42−2.32(m,22H),3.7
3(s,3H),3.88−3.99(m,1H),
4.30−4.40(m,1H),5.82(dt,J
=15.6,1.6Hz,1H),6.98(dt,J
=15.6,7.1Hz,1H) IR(neat);3400,2930,2859,2
235,1724,1702,1656,1438,1
384,1283,1204,1042,993c
m-1。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.42-2.32 (m, 22H), 3.7
3 (s, 3H), 3.88-3.99 (m, 1H),
4.30-4.40 (m, 1H), 5.82 (dt, J
= 15.6, 1.6 Hz, 1H), 6.98 (dt, J
= 15.6, 7.1 Hz, 1H) IR (neat); 3400, 2930, 2859, 2
235,1724,1702,1656,1438,1
384,1283,1204,1042,993c
m -1 .
【0087】実施例8 (2E)−9−デオキシ−9β−クロロ−16,17,
18,19,20−ペンタノル−15,15−テトラメ
チレン−2,3,13,14−テトラデヒドロ−PGF
1α(化合物16) 実施例7で得た化合物を用い、実施例4と実質的に同様
にして、標記化合物を得た。Example 8 (2E) -9-Deoxy-9β-chloro-16,17,
18,19,20-pentanor-15,15-tetramethylene-2,3,13,14-tetradehydro-PGF
Using 1 alpha (Compound 16) The compound obtained in Example 7, in substantially the same manner as in Example 4 to give the title compound.
【0088】1H−NMR(CDCl3,300MHz)
δppm;1.49−1.98(m,19H),2.0
8−2.34(m,4H),3.88−3.98(m,
1H),4.29−4.38(m,1H),5.85
(dt,J=15.6,1.4Hz,1H),7.06
(dt,J=15.6,6.9Hz,1H) IR(neat);3367,2935,2859,2
235,1696,1652,1439,1418,1
306,1283,1219,1075,988,94
4,909,881,802,757,668,540
cm-1。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.49-1.98 (m, 19H), 2.0
8-2.34 (m, 4H), 3.88-3.98 (m, 4H)
1H), 4.29-4.38 (m, 1H), 5.85
(Dt, J = 15.6, 1.4 Hz, 1H), 7.06
(Dt, J = 15.6, 6.9 Hz, 1H) IR (neat); 3367, 2935, 2859, 2
235,1696,1652,1439,1418,1
306,1283,1219,1075,988,94
4,909,881,802,757,668,540
cm -1 .
【0089】実施例9 9−デオキシ−9β−クロロ−16,17,18,1
9,20−ペンタノル−15,15−ペンタメチレン−
2,2,3,3,13,14−ヘキサデヒドロ−PGF
1α メチルエステル(化合物31) (1)実施例1(2)において、5−カルボメトキシペ
ンチル亜鉛(II)ヨージドの代わりに5−カルボメトキ
シ−4−ペンチニル亜鉛(II)ヨージドを用い、実施例
1(2)と実質的に同様にして、16,17,18,1
9,20−ペンタノル−15,15−ペンタメチレン−
2,2,3,3,13,14−ヘキサデヒドロ−PGE
1 メチルエステル 11−tert−ブチルジメチル
シリル−15−トリエチルシリル エーテルを得た。Example 9 9-deoxy-9β-chloro-16,17,18,1
9,20-pentanor-15,15-pentamethylene-
2,2,3,3,13,14-hexadehydro-PGF
1 α-methyl ester (Compound 31) (1) Example 1 was repeated using 5-carbomethoxy-4-pentynylzinc (II) iodide instead of 5-carbomethoxypentylzinc (II) iodide. 16, 17, 18, 1 in substantially the same manner as 1 (2)
9,20-pentanor-15,15-pentamethylene-
2,2,3,3,13,14-hexadehydro-PGE
1 methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether was obtained.
【0090】1H−NMR(CDCl3,200MHz)
δppm;0.11(s,3H),0.13(s,3
H),0.56−0.73(m,6H),0.81−
1.03(m,9H),0.90(s,9H),1.1
0−1.88(m,16H),2.10−2.40
(m,3H),2.19(dd,J=18.4,6.8
Hz,1H),2.61−2.78(m,1H),2.
70(dd,J=18.4,6.5Hz,2H),3.
75(s,3H),4.24−4.38(m,1H) IR(neat);2935,2875,2858,2
238,1748,1718,1462,1435,1
376,1256,1098,1005,869,83
8,779,744,671cm-1。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 0.11 (s, 3H), 0.13 (s, 3
H), 0.56-0.73 (m, 6H), 0.81-
1.03 (m, 9H), 0.90 (s, 9H), 1.1
0-1.88 (m, 16H), 2.10-2.40
(M, 3H), 2.19 (dd, J = 18.4, 6.8)
Hz, 1H), 2.61-2.78 (m, 1H), 2.
70 (dd, J = 18.4, 6.5 Hz, 2H);
75 (s, 3H), 4.24-4.38 (m, 1H) IR (neat); 2935, 2875, 2858, 2
238, 1748, 1718, 1462, 1435, 1
376, 1256, 1098, 1005, 869, 83
8,779,744,671 cm -1 .
【0091】(2)上記(1)で得た化合物を用い、実
施例1(3)と実質的に同様にして、16,17,1
8,19,20−ペンタノル−15,15−ペンタメチ
レン−2,2,3,3,13,14−ヘキサデヒドロ−
PGF1α メチルエステル 11−tert−ブチル
ジメチルシリル−15−トリエチルシリル エーテルお
よび16,17,18,19,20−ペンタノル−1
5,15−ペンタメチレン−2,2,3,3,13,1
4−ヘキサデヒドロ−PGF1β メチルエステル11
−tert−ブチルジメチルシリル−15−トリエチル
シリル エーテルを得た。(2) Using the compound obtained in the above (1), 16, 17, 1
8,19,20-pentanor-15,15-pentamethylene-2,2,3,3,13,14-hexadehydro-
PGF 1 alpha methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether and 16,17,18,19,20- Pentanoru -1
5,15-pentamethylene-2,2,3,3,13,1
4-Hexadehydro-PGF 1 β methyl ester 11
-Tert-Butyldimethylsilyl-15-triethylsilyl ether was obtained.
【0092】16,17,18,19,20−ペンタノ
ル−15,15−ペンタメチレン−2,2,3,3,1
3,14−ヘキサデヒドロ−PGF1α メチルエステ
ル11−tert−ブチルジメチルシリル−15−トリ
エチルシリル エーテル1 H−NMR(CDCl3,200MHz)δppm;
0.10(s,3H),0.12(s,3H),0.5
6−0.74(m,6H),0.80−1.04(m,
9H),0.89(s,9H),1.10−2.08
(m,19H),2.36(t,J=6.8Hz,2
H),2.43−2.53(m,1H),2.59
(d,J=9.7Hz,1H),3.75(s,3
H),4.08−4.20(m,1H),4.26−
4.34(m,1H) IR(neat);3467,2934,2875,2
858,2237,1719,1461,1435,1
361,1254,1179,1080,1004,8
69,838,778,743cm-1。16, 17, 18, 19, 20-pentanor-15,15-pentamethylene-2,2,3,3,1
3,14- Hekisadehidoro-PGF 1 alpha methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether 1 H-NMR (CDCl 3, 200MHz) δppm;
0.10 (s, 3H), 0.12 (s, 3H), 0.5
6-0.74 (m, 6H), 0.80-1.04 (m,
9H), 0.89 (s, 9H), 1.10-2.08
(M, 19H), 2.36 (t, J = 6.8 Hz, 2
H), 2.43-2.53 (m, 1H), 2.59
(D, J = 9.7 Hz, 1H), 3.75 (s, 3
H), 4.08-4.20 (m, 1H), 4.26-
4.34 (m, 1H) IR (neat); 3467, 2934, 2875, 2
858, 2237, 1719, 1461, 1435, 1
361, 1254, 1179, 1080, 1004, 8
69,838,778,743 cm -1 .
【0093】16,17,18,19,20−ペンタノ
ル−15,15−ペンタメチレン−2,2,3,3,1
3,14−ヘキサデヒドロ−PGF1β メチルエステ
ル11−tert−ブチルジメチルシリル−15−トリ
エチルシリル エーテル1 H−NMR(CDCl3,200MHz)δppm;
0.08(s,3H),0.09(s,3H),0.5
6−0.74(m,6H),0.82−1.03(m,
9H),0.89(s,9H),1.14−1.96
(m,20H),2.25(dd,J=9.3,6.0
Hz,1H),2.35(t,J=6.6Hz,2
H),3.76(s,3H),3.92−4.08
(m,1H),4.17−4.30(m,1H) IR(neat);3435,2934,2875,2
857,2238,1719,1461,1436,1
360,1255,1180,1079,1005,9
25,905,869,837,778,743c
m-1。16, 17, 18, 19, 20-pentanor-15,15-pentamethylene-2,2,3,3,1
3,14-hexadehydro-PGF 1 β methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether 1 H-NMR (CDCl3, 200 MHz) δ ppm;
0.08 (s, 3H), 0.09 (s, 3H), 0.5
6-0.74 (m, 6H), 0.82-1.03 (m,
9H), 0.89 (s, 9H), 1.14 to 1.96.
(M, 20H), 2.25 (dd, J = 9.3, 6.0).
Hz, 1H), 2.35 (t, J = 6.6 Hz, 2
H), 3.76 (s, 3H), 3.92-4.08.
(M, 1H), 4.17-4.30 (m, 1H) IR (neat); 3435, 2934, 2875, 2
857, 2238, 1719, 1461, 1436, 1
360, 1255, 1180, 1079, 1005, 9
25,905,869,837,778,743c
m -1 .
【0094】(3)上記(2)で得た16,17,1
8,19,20−ペンタノル−15,15−ペンタメチ
レン−2,2,3,3,13,14−ヘキサデヒドロ−
PGF1α メチルエステル 11−tert−ブチル
ジメチルシリル−15−トリエチルシリル エーテルを
用い、実施例1(4)と実質的に同様にして、標記化合
物を得た。(3) 16, 17, 1 obtained in (2) above
8,19,20-pentanor-15,15-pentamethylene-2,2,3,3,13,14-hexadehydro-
With PGF 1 alpha methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether, in substantially the same manner as in Example 1 (4), to give the title compound.
【0095】1H−NMR(CDCl3,200MH
z)δppm;1.14−1.96(m,16H),
2.03−2.48(m,8H),3.77(s,3
H),3.88−4.03(m,1H),4.29−
4.43(m,1H) IR(neat);3389,2935,2858,2
237,1716,1436,1331,1257,1
179,1134,1077,963,904,85
0,820,753,533cm-1。 1 H-NMR (CDCl 3 , 200 MH
z) δ ppm; 1.14-1.96 (m, 16H),
2.03-2.48 (m, 8H), 3.77 (s, 3
H), 3.88-4.03 (m, 1H), 4.29-
4.43 (m, 1H) IR (neat); 3389, 2935, 2858, 2
237, 1716, 1436, 1331, 1257, 1
179, 1134, 1077, 963, 904, 85
0,820,753,533 cm -1 .
【0096】実施例10 9−デオキシ−9β−クロロ−16,17,18,1
9,20−ペンタノル−15,15−ペンタメチレン−
2,2,3,3,13,14−ヘキサデヒドロ−PGF
1α(化合物32) 実施例9で得た化合物を用い、実施例4と実質的に同様
にして、標記化合物を得た。Example 10 9-Deoxy-9β-chloro-16,17,18,1
9,20-pentanor-15,15-pentamethylene-
2,2,3,3,13,14-hexadehydro-PGF
1 α (Compound 32) The title compound was obtained in substantially the same manner as in Example 4 using the compound obtained in Example 9.
【0097】1H−NMR(CDCl3,300MHz)
δppm;1.13−1.98(m,16H),2.0
2−2.46(m,3H),2.33(dd,J=1
0.0,6.3Hz,1H),2.40(t,J=6.
2Hz,2H),2.60−3.40(m,3H),
3.88−3.98(m,1H),4.31−4.40
(m,1H) IR(neat);3367,2935,2859,2
624,2236,1691,1445,1332,1
257,1059,961,905,850,757,
667,594cm-1。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.13-1.98 (m, 16H), 2.0
2-2.46 (m, 3H), 2.33 (dd, J = 1
0.0, 6.3 Hz, 1H), 2.40 (t, J = 6.
2Hz, 2H), 2.60-3.40 (m, 3H),
3.88-3.98 (m, 1H), 4.31-4.40
(M, 1H) IR (neat); 3367, 2935, 2859, 2
624, 2236, 1691, 1445, 1332, 1
257, 1059, 961, 905, 850, 757,
667,594 cm -1 .
【0098】実施例11 3−オキサ−9−デオキシ−9β−クロロ−16,1
7,18,19,20−テトラノル−15,15−ペン
タメチレン−13,14−ジデヒドロ−PGF1α メ
チルエステル(化合物38) (1)実施例1(2)において、5−カルボメトキシペ
ンチル亜鉛(II)ヨージドの代わりに4−オキサ−5−
カルボメトキシペンチル亜鉛(II)ヨージドを用い、実
施例1(2)と実質的に同様にして、3−オキサ−1
6,17,18,19,20−ペンタノル−15,15
−ペンタメチレン−13,14−ジデヒドロ−PGE1
メチルエステル 11−tert−ブチルジメチルシ
リル−15−トリエチルシリル エーテルを得た。Example 11 3-oxa-9-deoxy-9β-chloro-16,1
7,18,19,20- tetranor -15,15- in pentamethylene-13,14-didehydro-PGF 1 alpha methyl ester (Compound 38) (1) Example 1 (2), 5-carbomethoxy-pentyl zinc ( II) 4-oxa-5 instead of iodide
3-oxa-1 was prepared in substantially the same manner as in Example 1 (2) using carbomethoxypentyl zinc (II) iodide.
6,17,18,19,20-pentanor-15,15
-Pentamethylene-13,14-didehydro-PGE 1
The methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether was obtained.
【0099】1H−NMR(CDCl3,200MHz)
δppm;0.09(s,3H),0.13(s,3
H),0.55−0.74(m,6H),0.86−
1.02(m,9H),0.89(s,9H),1.1
6−1.90(m,16H),2.08−2.29
(m,1H),2.18(dd,J=18.2,6.8
Hz,1H),2.61−2.80(m,1H),2.
73(dd,J=9.2,6.6Hz,1H),3.5
3(t,J=6.4Hz,2H),3.76(s,3
H),4.079(s,2H),4.24−4.37
(m,1H) IR(neat);2935,2875,2858,2
234,1748,1461,1411,1375,1
290,1254,1235,1206,1141,1
101,1059,1005,870,839,81
1,779,743,671cm-1。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 0.09 (s, 3H), 0.13 (s, 3
H), 0.55-0.74 (m, 6H), 0.86-
1.02 (m, 9H), 0.89 (s, 9H), 1.1
6-1.90 (m, 16H), 2.08-2.29
(M, 1H), 2.18 (dd, J = 18.2, 6.8
Hz, 1H), 2.61-2.80 (m, 1H), 2.
73 (dd, J = 9.2, 6.6 Hz, 1H), 3.5
3 (t, J = 6.4 Hz, 2H), 3.76 (s, 3
H), 4.079 (s, 2H), 4.24-4.37.
(M, 1H) IR (neat); 2935, 2875, 2858, 2
234, 1748, 1461, 1411, 1375, 1
290, 1254, 1235, 1206, 1141, 1
101, 1059, 1005, 870, 839, 81
1,779,743,671 cm -1 .
【0100】(2)上記(1)で得た化合物を用い、実
施例1(3)と実質的に同様にして、3−オキサ−1
6,17,18,19,20−ペンタノル−15,15
−ペンタメチレン−13,14−ジデヒドロ−PGF1
α メチルエステル 11−tert−ブチルジメチル
シリル−15−トリエチルシリル エーテルおよび3−
オキサ−16,17,18,19,20−ペンタノル−
15,15−ペンタメチレン−13,14−ジデヒドロ
−PGF1β メチルエステル 11−tert−ブチ
ルジメチルシリル−15−トリエチルシリル エーテル
を得た。(2) Using the compound obtained in the above (1), 3-oxa-1 was prepared in substantially the same manner as in Example 1 (3).
6,17,18,19,20-pentanor-15,15
-Pentamethylene-13,14-didehydro-PGF 1
α methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether and 3-
Oxa-16,17,18,19,20-pentanor-
15,15 to obtain pentamethylene-13,14-didehydro-PGF 1 beta methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether.
【0101】3−オキサ−16,17,18,19,2
0−ペンタノル−15,15−ペンタメチレン−13,
14−ジデヒドロ−PGF1α メチルエステル 11
−tert−ブチルジメチルシリル−15−トリエチル
シリル エーテル1 H−NMR(CDCl3,200MHz)δppm;
0.10(s,3H),0.11(s,3H),0.5
6−0.73(m,6H),0.84−1.04(m,
9H),0.89(s,9H),1.13−2.15
(m,19H),2.43−2.54(m,1H),
2.61(d,J=9.2Hz,1H),3.55
(t,J=6.54Hz,2H),3.76(s,3
H),4.06−4.21(m,1H),4.08
(s,2H),4.24−4.33(m,1H) IR(neat);3468,2933,2874,2
857,2231,1758,1461,1441,1
253,1208,1140,1096,1055,1
004,885,869,838,778,743cm
-1。3-oxa-16,17,18,19,2
0-pentanor-15,15-pentamethylene-13,
14-didehydro-PGF 1 alpha methyl ester 11
-Tert-butyldimethylsilyl-15-triethylsilyl ether 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.10 (s, 3H), 0.11 (s, 3H), 0.5
6-0.73 (m, 6H), 0.84-1.04 (m,
9H), 0.89 (s, 9H), 1.13-2.15
(M, 19H), 2.43-2.54 (m, 1H),
2.61 (d, J = 9.2 Hz, 1H), 3.55
(T, J = 6.54 Hz, 2H), 3.76 (s, 3
H), 4.06-4.21 (m, 1H), 4.08.
(S, 2H), 4.24-4.33 (m, 1H) IR (neat); 3468, 2933, 2874, 2
857, 2231, 1758, 1461, 1441, 1
253, 1208, 1140, 1096, 1055, 1
004,885,869,838,778,743cm
-1 .
【0102】3−オキサ−16,17,18,19,2
0−ペンタノル−15,15−ペンタメチレン−13,
14−ジデヒドロ−PGF1β メチルエステル 11
−tert−ブチルジメチルシリル−15−トリエチル
シリル エーテル1 H−NMR(CDCl3,200MHz)δppm;
0.07(s,3H),0.09(s,3H),0.5
5−0.74(m,6H),0.80−1.03(m,
9H),0.89(s,9H),1.14−1.95
(m,20H),2.26(dd,J=9.3,6.3
Hz,1H),3.54(t,J=6.2Hz,2
H),3.76(s,3H),3.94−4.30
(m,2H),4.08(s,2H) IR(neat);3435,2933,2875,2
857,2232,1758,1461,1441,1
360,1290,1253,1139,1097,1
059,1004,925,905,868,836,
811,777,743cm-1。3-oxa-16,17,18,19,2
0-pentanor-15,15-pentamethylene-13,
14-didehydro-PGF 1 beta methyl ester 11
-Tert-butyldimethylsilyl-15-triethylsilyl ether 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.07 (s, 3H), 0.09 (s, 3H), 0.5
5-0.74 (m, 6H), 0.80-1.03 (m,
9H), 0.89 (s, 9H), 1.14-1.95
(M, 20H), 2.26 (dd, J = 9.3, 6.3)
Hz, 1H), 3.54 (t, J = 6.2 Hz, 2
H), 3.76 (s, 3H), 3.94-4.30.
(M, 2H), 4.08 (s, 2H) IR (neat); 3435, 2933, 2875, 2
857, 2232, 1758, 1461, 1441, 1
360, 1290, 1253, 1139, 1097, 1
059,1004,925,905,868,836
811,777,743 cm -1 .
【0103】(3)上記(2)で得た3−オキサ−1
6,17,18,19,20−ペンタノル−15,15
−ペンタメチレン−13,14−ジデヒドロ−PGF1
α メチルエステル 11−tert−ブチルジメチル
シリル−15−トリエチルシリルエーテルを用い、実施
例1(4)と実質的に同様にして、標記化合物を得た。(3) 3-oxa-1 obtained in the above (2)
6,17,18,19,20-pentanor-15,15
-Pentamethylene-13,14-didehydro-PGF 1
Using α-methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether, the title compound was obtained in substantially the same manner as in Example 1 (4).
【0104】1H−NMR(CDCl3,200MHz)
δppm;1.14−2.38(m,22H),3.5
0−3.64(m,2H),3.76(s,3H),
3.88−4.03(m,1H),4.09(s,2
H),4.29−4.46(m,1H) IR(neat);3400,2934,2858,2
235,1755,1746,1443,1341,1
284,1214,1137,1061,964,90
4,850,800,704,418,405cm-1。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 1.14 to 2.38 (m, 22H), 3.5
0-3.64 (m, 2H), 3.76 (s, 3H),
3.88-4.03 (m, 1H), 4.09 (s, 2
H), 4.29-4.46 (m, 1H) IR (neat); 3400, 2934, 2858, 2
235, 1755, 1746, 1443, 1341, 1
284,1214,1137,1061,964,90
4,850,800,704,418,405 cm -1 .
【0105】実施例12 3−オキサ−9−デオキシ−9β−クロロ−16,1
7,18,19,20−ペンタノル−15,15−ペン
タメチレン−13,14−ジデヒドロ−PGF1α(化
合物39) 実施例11で得た化合物を用い、実施例2と実質的に同
様にして、標記化合物を得た。Example 12 3-oxa-9-deoxy-9β-chloro-16,1
7,18,19,20- Pentanoru -15,15- pentamethylene 13,14-didehydro-PGF 1 alpha (Compound 39) Using the compound obtained in Example 11, in substantially the same manner as in Example 2 To give the title compound.
【0106】1H−NMR(CDCl3,300MHz)
δppm;1.13−2.39(m,18H),2.2
3(dd,J=13.1,8.3Hz,1H),2.3
2(dd,J=9.9,6.4Hz,1H),3.07
−4.20(m,6H),4.09(s,2H),4.
31−4.41(m,1H) IR(neat);3368,2934,2858,2
235,1734,1445,1342,1234,1
180,1133,1059,962,904,85
0,801,676cm-1。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.13-2.39 (m, 18H), 2.2
3 (dd, J = 13.1, 8.3 Hz, 1H), 2.3
2 (dd, J = 9.9, 6.4 Hz, 1H), 3.07
-4.20 (m, 6H), 4.09 (s, 2H), 4.
31-4.41 (m, 1H) IR (neat); 3368, 2934, 2858, 2
235,1734,1445,1342,1234,1
180, 1133, 1059, 962, 904, 85
0,801,676 cm -1 .
【0107】実施例13 3−チア−9−デオキシ−9β−クロロ−16,17,
18,19,20−ペンタノル−15,15−ヘキサメ
チレン−13,14−ジデヒドロ−PGF1αメチルエ
ステル(化合物49) (1)実施例3(2)において、(E)−5−カルボメ
トキシ−4−ペンテニル亜鉛(II)ヨージドの代わりに
4−チア−5−カルボメトキシペンチル亜鉛(II)ヨー
ジドを用い、実施例3(2)と実質的にと同様にして、
3−チア−16,17,18,19,20−ペンタノル
−15,15−ヘキサメチレン−13,14−ジデヒド
ロ−PGE1 メチルエステル 11−tert−ブチ
ルジメチルシリル−15−トリエチルシリル エーテル
を得た。Example 13 3-Thia-9-deoxy-9β-chloro-16,17,
18,19,20- Pentanoru -15,15- in hexamethylene 13,14-didehydro-PGF 1 alpha methyl ester (Compound 49) (1) Example 3 (2), (E) -5- carbomethoxy - Using 4-thia-5-carbomethoxypentylzinc (II) iodide instead of 4-pentenylzinc (II) iodide, substantially as in Example 3 (2),
3-Thia-16,17,18,19,20-pentanor-15,15-hexamethylene-13,14-didehydro-PGE 1 methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether was obtained.
【0108】1H−NMR(CDCl3,200MH
z)δppm;0.09(s,3H),0.13(s,
3H),0.55−0.75(m,6H),0.80−
1.05(m,9H),0.90(s,9H),1.1
5−2.30(m,20H),2.50−2.80
(m,4H),3.22(s,2H),3.74(s,
3H),4.23−4.37(m,1H) IR(neat);2930,2874,2858,2
229,1746,1461,1436,1411,1
375,1281,1258,1235,1192,1
131,1067,1007,940,837,77
8,743,670,590cm-1。 1 H-NMR (CDCl3, 200 MH
z) δ ppm; 0.09 (s, 3H), 0.13 (s,
3H), 0.55-0.75 (m, 6H), 0.80-
1.05 (m, 9H), 0.90 (s, 9H), 1.1
5-2.30 (m, 20H), 2.50-2.80
(M, 4H), 3.22 (s, 2H), 3.74 (s,
3H), 4.23-4.37 (m, 1H) IR (neat); 2930, 2874, 2858, 2
229, 1746, 1461, 1436, 1411, 1
375,1281,1258,1235,1192,1
131,1067,1007,940,837,77
8,743,670,590 cm -1 .
【0109】(2)上記(1)で得た化合物を用い、実
施例1(3)と実質的に同様にして、3−チア−16,
17,18,19,20−ペンタノル−15,15−ヘ
キサメチレン−13,14−ジデヒドロ−PGF1α
メチルエステル 11−tert−ブチルジメチルシリ
ル−15−トリエチルシリル エーテルおよび3−チア
−16,17,18,19,20−ペンタノル−15,
15−ヘキサメチレン−13,14−ジデヒドロ−PG
F1β メチルエステル 11−tert−ブチルジメ
チルシリル−15−トリエチルシリル エーテルを得
た。(2) Using the compound obtained in the above (1), 3-thia-16,16 was obtained in substantially the same manner as in Example 1 (3).
17,18,19,20- Pentanoru -15,15- hexamethylene-13,14-didehydro -PGF 1 α
Methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether and 3-thia-16,17,18,19,20-pentanor-15
15-Hexamethylene-13,14-didehydro-PG
F 1 β methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether was obtained.
【0110】3−チア−16,17,18,19,20
−ペンタノル−15,15−ヘキサメチレン−13,1
4−ジデヒドロ−PGF1α メチルエステル 11−
tert−ブチルジメチルシリル−15−トリエチルシ
リル エーテル1 H−NMR(CDCl3,200MHz)δppm;
0.10(s,3H),0.12(s,3H),0.5
6−0.72(m,6H),0.84−1.04(m,
9H),0.89(s,9H),1.19−2.07
(m,21H),2.42−2.52(m,1H),
2.55−2.72(m,1H),2.66(t,J=
7.0Hz,2H),3.23(s,2H),3.74
(s,3H),4.06−4.20(m,1H),4.
24−4.34(m,1H) IR(neat);3523,2930,2874,2
857,2224,1739,1460,1436,1
412,1388,1361,1279,1256,1
192,1131,1065,1005,868,83
7,778,743cm-1。3-thia-16,17,18,19,20
-Pentanor-15,15-hexamethylene-13,1
4-didehydro-PGF 1 alpha methyl ester 11-
tert-butyldimethylsilyl-15-triethylsilyl ether 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.10 (s, 3H), 0.12 (s, 3H), 0.5
6-0.72 (m, 6H), 0.84-1.04 (m,
9H), 0.89 (s, 9H), 1.19-2.07
(M, 21H), 2.42-2.52 (m, 1H),
2.55-2.72 (m, 1H), 2.66 (t, J =
7.0 Hz, 2H), 3.23 (s, 2H), 3.74
(S, 3H), 4.06-4.20 (m, 1H), 4.
24-4.34 (m, 1H) IR (neat); 3523, 2930, 2874, 2
857, 2224, 1739, 1460, 1436, 1
412, 1388, 1361, 1279, 1256, 1
192,1131,1065,1005,868,83
7,778,743 cm -1 .
【0111】3−チア−16,17,18,19,20
−ペンタノル−15,15−ヘキサメチレン−13,1
4−ジデヒドロ−PGF1β メチルエステル 11−
tert−ブチルジメチルシリル−15−トリエチルシ
リル エーテル1 H−NMR(CDCl3,200MHz)δppm;
0.08(s,3H),0.09(s,3H),0.5
7−0.73(m,6H),0.83−1.04(m,
9H),0.89(s,9H),1.18−1.98
(m,20H),1.89(t,J=6.4Hz,2
H),2.25(dd,J=9.3,6.0Hz,1
H),2.65(t,J=7.0Hz,2H),3.2
3(s,2H),3.74(s,3H),3.92−
4.07(m,1H),4.17−4.30(m,1
H) IR(neat);3435,2946,2930,2
874,2857,2229,1739,1460,1
437,1412,1361,1282,1256,1
192,1131,1066,1006,836,77
7,743,407cm-1。3-thia-16,17,18,19,20
-Pentanor-15,15-hexamethylene-13,1
4-didehydro-PGF 1 beta methyl ester 11-
tert-butyldimethylsilyl-15-triethylsilyl ether 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.08 (s, 3H), 0.09 (s, 3H), 0.5
7-0.73 (m, 6H), 0.83-1.04 (m,
9H), 0.89 (s, 9H), 1.18-1.98
(M, 20H), 1.89 (t, J = 6.4 Hz, 2
H), 2.25 (dd, J = 9.3, 6.0 Hz, 1
H), 2.65 (t, J = 7.0 Hz, 2H), 3.2
3 (s, 2H), 3.74 (s, 3H), 3.92-
4.07 (m, 1H), 4.17-4.30 (m, 1
H) IR (neat); 3435, 2946, 2930, 2
874, 2857, 2229, 1739, 1460, 1
437, 1412, 1361, 1282, 1256, 1
192,1131,1066,1006,836,77
7,743,407 cm -1 .
【0112】(3)上記(2)で得た3−チア−16,
17,18,19,20−ペンタノル−15,15−ヘ
キサメチレン−13,14−ジデヒドロ−PGF1α
メチルエステル 11−tert−ブチルジメチルシリ
ル−15−トリエチルシリルエーテルを用い、実施例1
(4)と実質的に同様にして、標記化合物を得た。(3) 3-thia-16, obtained in the above (2)
17,18,19,20- Pentanoru -15,15- hexamethylene-13,14-didehydro -PGF 1 α
Example 1 Using methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether
The title compound was obtained in substantially the same manner as (4).
【0113】1H−NMR(CDCl3,300MHz)
δppm;0.84−2.34(m,24H),2.6
6(t,J=6.9Hz,2H),3.23(s,2
H),3.74(s,3H),3.90−4.00
(m,1H),4.31−4.40(m,1H) IR(neat);3400,2929,2856,2
229,1734,1583,1438,1282,1
196,1135,1089,1023,911,85
6,797,698,594cm-1。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 0.84-2.34 (m, 24H), 2.6
6 (t, J = 6.9 Hz, 2H), 3.23 (s, 2
H), 3.74 (s, 3H), 3.90-4.00.
(M, 1H), 4.31-4.40 (m, 1H) IR (neat); 3400, 2929, 2856, 2
229, 1734, 1583, 1438, 1282, 1
196,1135,1089,1023,911,85
6,797,698,594 cm -1 .
【0114】実施例14 3−チア−9−デオキシ−9β−クロロ−16,17,
18,19,20−ペンタノル−15,15−ヘキサメ
チレン−13,14−ジデヒドロ−PGF1α(化合物
50) 実施例13で得た化合物を用い、実施例2と実質的に同
様にして、標記化合物を得た。Example 14 3-Thia-9-deoxy-9β-chloro-16,17,
18,19,20- Pentanoru -15,15- hexamethylene 13,14-didehydro-PGF 1 alpha (Compound 50) Using the compound obtained in Example 13, in substantially the same manner as in Example 2, the title The compound was obtained.
【0115】1H−NMR(CDCl3,200MHz)
δppm;0.82−2.38(m,22H),2.5
0−3.00(m,5H),3.23(s,2H),
3.88−4.03(m,1H),4.29−4.43
(m,1H) IR(neat);3368,2929,2857,2
230,1712,1459,1445,1383,1
283,1196,1138,1024,910,75
6cm-1。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 0.82-2.38 (m, 22H), 2.5
0-3.00 (m, 5H), 3.23 (s, 2H),
3.88-4.03 (m, 1H), 4.29-4.43
(M, 1H) IR (neat); 3368,2929,2857,2
230, 1712, 1459, 1445, 1383, 1
283, 1196, 1138, 1024, 910, 75
6 cm -1 .
【0116】実施例15 3−チア−9−デオキシ−9β−クロロ−16,17,
18,19,20−ペンタノル−15,15−ペンタメ
チレン−13,14−ジデヒドロ−PGF1αメチルエ
ステル(化合物45) (1)実施例1(2)において、5−カルボメトキシペ
ンチル亜鉛(II)ヨージドの代わりに4−チア−5−カ
ルボメトキシペンチル亜鉛(II)ヨージドを用い、実施
例1(2)と実質的にと同様にして、3−チア−16,
17,18,19,20−ペンタノル−15,15−ペ
ンタメチレン−13,14−ジデヒドロ−PGE1 メ
チルエステル 11−tert−ブチルジメチルシリル
−15−トリエチルシリル エーテルを得た。Example 15 3-Thia-9-deoxy-9β-chloro-16,17,
18,19,20- Pentanoru -15,15- pentamethylene 13,14-didehydro-PGF 1 alpha methyl ester (Compound 45) (1) in Example 1 (2), 5-carbomethoxy-pentyl zinc (II) Using 4-thia-5-carbomethoxypentyl zinc (II) iodide instead of iodide, 3-thia-16, substantially as in Example 1 (2).
17,18,19,20-Pentanol-15,15-pentamethylene-13,14-didehydro-PGE 1 methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether was obtained.
【0117】1H−NMR(CDCl3,200MHz)
δppm;0.09(s,3H),0.13(s,3
H),0.56−0.74(m,6H),0.80−
1.02(m,9H),0.90(s,9H),1.1
2−1.90(m,16H),2.05−2.30
(m,1H),2.18(dd,J=18.1,6.9
Hz,1H),2.56−2.80(m,2H),2.
63(t,J=6.6Hz,2H),3.22(s,2
H),3.74(s,3H),4.24−4.37
(m,1H) IR(neat);2934,2875,2858,2
233,1747,1461,1438,1411,1
376,1280,1257,1133,1099,1
058, 1006,869,838,811,77
9,743,671cm-1。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 0.09 (s, 3H), 0.13 (s, 3
H), 0.56-0.74 (m, 6H), 0.80-
1.02 (m, 9H), 0.90 (s, 9H), 1.1
2-1.90 (m, 16H), 2.05-2.30
(M, 1H), 2.18 (dd, J = 18.1, 6.9)
Hz, 1H), 2.56-2.80 (m, 2H), 2.
63 (t, J = 6.6 Hz, 2H), 3.22 (s, 2
H), 3.74 (s, 3H), 4.24-4.37.
(M, 1H) IR (neat); 2934, 2875, 2858, 2
233,1747,1461,1438,1411,1
376,1280,1257,1133,1099,1
058, 1006, 869, 838, 811, 77
9,743,671 cm -1 .
【0118】(2)上記(1)で得た化合物を用い、実
施例1(3)と実質的に同様にして、3−チア−16,
17,18,19,20−ペンタノル−15,15−ペ
ンタメチレン−13,14−ジデヒドロ−PGF1α
メチルエステル 11−tert−ブチルジメチルシリ
ル−15−トリエチルシリル エーテルおよび3−チア
−16,17,18,19,20−ペンタノル−15,
15−ペンタメチレン−13,14−ジデヒドロ−PG
F1β メチルエステル 11−tert−ブチルジメ
チルシリル−15−トリエチルシリル エーテルを得
た。(2) Using the compound obtained in (1) above, 3-thia-16, substantially 16 as in Example 1 (3)
17,18,19,20- Pentanoru -15,15- pentamethylene-13,14-didehydro -PGF 1 α
Methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether and 3-thia-16,17,18,19,20-pentanor-15
15-pentamethylene-13,14-didehydro-PG
F 1 β methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether was obtained.
【0119】3−チア−16,17,18,19,20
−ペンタノル−15,15−ペンタメチレン−13,1
4−ジデヒドロ−PGF1α メチルエステル 11−
tert−ブチルジメチルシリル−15−トリエチルシ
リル エーテル1 H−NMR(CDCl3,200MHz)δppm;
0.10(s,3H),0.12(s,3H),0.5
6−0.74(m,6H),0.82−1.04(m,
9H),0.89(s,9H),1.16−2.07
(m,19H),2.48(dd,J=8.4,1.3
Hz,1H),2.58(d,J=9.4Hz,1
H),2.66(t,J=7.0Hz,2H),3.2
3(s,2H),3.74(s,3H),4.06−
4.20(m,1H),4.24−4.34(m,1
H) IR(neat);3468,2933,2875,2
857,2230,1738,1461,1438,1
412,1278,1255,1098,1056,1
004,869,838,778,743cm-1。3-thia-16,17,18,19,20
-Pentanor-15,15-pentamethylene-13,1
4-didehydro-PGF 1 alpha methyl ester 11-
tert-butyldimethylsilyl-15-triethylsilyl ether 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.10 (s, 3H), 0.12 (s, 3H), 0.5
6-0.74 (m, 6H), 0.82-1.04 (m,
9H), 0.89 (s, 9H), 1.16 to 2.07
(M, 19H), 2.48 (dd, J = 8.4, 1.3).
Hz, 1H), 2.58 (d, J = 9.4 Hz, 1
H), 2.66 (t, J = 7.0 Hz, 2H), 3.2
3 (s, 2H), 3.74 (s, 3H), 4.06-
4.20 (m, 1H), 4.24-4.34 (m, 1
H) IR (neat); 3468, 2933, 2875, 2
857, 2230, 1738, 1461, 1438, 1
412, 1278, 1255, 1098, 1056, 1
004,869,838,778,743 cm -1 .
【0120】3−チア−16,17,18,19,20
−ペンタノル−15,15−ペンタメチレン−13,1
4−ジデヒドロ−PGF1β メチルエステル 11−
tert−ブチルジメチルシリル−15−トリエチルシ
リル エーテル(3)上記1 H−NMR(CDCl3,200MHz)δppm;
0.08(s,3H),0.09(s,3H),0.5
6−0.75(m,6H),0.80−1.02(m,
9H),0.89(s,9H),1.12−1.94
(m,20H),2.25(dd,J=9.2,5.9
Hz,1H),2.65(t,J=7.1Hz,2
H),3.23(s,2H),3.74(s,3H),
3.92−4.07(m,1H),4.16−4.30
(m,1H) IR(neat);3435,2932,2857,2
230,1738,1461,1438,1412,1
385,1289,1255,1132,1096,1
059,1005,925,905,869,836,
810,778,743cm-1。3-thia-16,17,18,19,20
-Pentanor-15,15-pentamethylene-13,1
4-didehydro-PGF 1 beta methyl ester 11-
tert-butyldimethylsilyl-15-triethylsilyl ether (3) 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.08 (s, 3H), 0.09 (s, 3H), 0.5
6-0.75 (m, 6H), 0.80-1.02 (m,
9H), 0.89 (s, 9H), 1.12-1.94.
(M, 20H), 2.25 (dd, J = 9.2, 5.9)
Hz, 1H), 2.65 (t, J = 7.1 Hz, 2
H), 3.23 (s, 2H), 3.74 (s, 3H),
3.92-4.07 (m, 1H), 4.16-4.30
(M, 1H) IR (neat); 3435, 2932, 2857, 2
230, 1738, 1461, 1438, 1412, 1
385,1289,1255,1132,1096,1
059,1005,925,905,869,836
810,778,743 cm -1 .
【0121】(3)上記(2)で得た3−チア−16,
17,18,19,20−ペンタノル−15,15−ペ
ンタメチレン−13,14−ジデヒドロ−PGF1α
メチルエステル 11−tert−ブチルジメチルシリ
ル−15−トリエチルシリルエーテルを用い、実施例1
(4)と実質的に同様にして、標記化合物を得た。(3) 3-thia-16, obtained in the above (2)
17,18,19,20- Pentanoru -15,15- pentamethylene-13,14-didehydro -PGF 1 α
Example 1 Using methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether
The title compound was obtained in substantially the same manner as (4).
【0122】1H−NMR(CDCl3,200MHz)
δppm;1.12−1.96(m,16H),2.0
0−2.38(m,6H),2.60−2.74(m,
2H),3.24(s,2H),3.75(s,3
H),3.88−4.03(m,1H),4.29−
4.43(m,1H) IR(neat);3390,2933,2857,2
235,1734,1438,1409,1331,1
283,1134,1065,1010,963,90
4,850,707,593cm-1。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 1.12-1.96 (m, 16H), 2.0
0-2.38 (m, 6H), 2.60-2.74 (m,
2H), 3.24 (s, 2H), 3.75 (s, 3
H), 3.88-4.03 (m, 1H), 4.29-
4.43 (m, 1H) IR (neat); 3390, 2933, 2857, 2
235, 1734, 1438, 1409, 1331, 1
283, 1134, 1065, 1010, 963, 90
4,850,707,593 cm -1 .
【0123】実施例16 3−チア−9−デオキシ−9β−クロロ−16,17,
18,19,20−ペンタノル−15,15−ペンタメ
チレン−13,14−ジデヒドロ−PGF1α(化合物
46) 実施例15で得た化合物を用い、実施例2と実質的に同
様にして、標記化合物を得た。Example 16 3-Thia-9-deoxy-9β-chloro-16,17,
18,19,20- Pentanoru -15,15- compounds used to obtain pentamethylene-13,14-didehydro-PGF 1 alpha (Compound 46) Example 15, in substantially the same manner as in Example 2, the title The compound was obtained.
【0124】1H−NMR(CDCl3,300MHz)
δppm;1.16−2.39(m,20H),2.6
0−4.42(m,7H),3.23(s,2H) IR(neat);368,2933,2857,22
35,1711,1445,1418,1384,13
32,1284,1180,1134,1059,96
1,904,850,785cm-1。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.16-2.39 (m, 20H), 2.6
0-4.42 (m, 7H), 3.23 (s, 2H) IR (neat); 368, 2933, 2857, 22
35, 1711, 1445, 1418, 1384, 13
32, 1284, 1180, 1134, 1059, 96
1,904,850,785 cm -1 .
【0125】実施例17 3−チア−9−デオキシ−9β−クロロ−16,17,
18,19,20−ペンタノル−15,15−テトラメ
チレン−13,14−ジデヒドロ−PGF1αメチルエ
ステル(化合物42) (1)実施例7(1)で得られた化合物を用い、実施例
1(2)において、5−カルボメトキシペンチル亜鉛
(II)ヨージドの代わりに4−チア−5−カルボメトキ
シペンチル亜鉛(II)ヨージドを用い、実施例1(2)
と実質的にと同様にして、3−チア−16,17,1
8,19,20−ペンタノル−15,15−テトラメチ
レン−13,14−ジデヒドロ−PGE1 メチルエス
テル 11−tert−ブチルジメチルシリル−15−
トリエチルシリル エーテルを得た。Example 17 3-Thia-9-deoxy-9β-chloro-16,17,
18,19,20- Pentanoru -15,15- tetramethylene 13,14-didehydro-PGF 1 alpha methyl ester (Compound 42) (1) using the compound obtained in Example 7 (1), Example 1 In Example (2), 4-thia-5-carbomethoxypentyl zinc (II) iodide was used in place of 5-carbomethoxy pentyl zinc (II) iodide in (2).
And 3-thia-16,17,1
8,19,20-pentanor-15,15-tetramethylene-13,14-didehydro-PGE 1 methyl ester 11-tert-butyldimethylsilyl-15
Triethylsilyl ether was obtained.
【0126】1H−NMR(CDCl3,200MHz)
δppm;0.10(s,3H),0.14(s,3
H),0.56−0.73(m,6H),0.78−
1.03(m,9H),0.90(s,9H),1.2
0−1.95(m,14H),2.17(dd,J=1
8.3,7.1Hz,1H),2.16−2.26
(m,1H),2.60−2.75(m,4H),3.
23(s,2H),3.75(s,3H),4.22
(m,1H) IR(neat);2953,2874,2858,2
234,1746,1462,1436,1411,1
376,1281,1258,1234,1119,1
058,1007,877,837,778,743,
670cm-1。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 0.10 (s, 3H), 0.14 (s, 3
H), 0.56-0.73 (m, 6H), 0.78-
1.03 (m, 9H), 0.90 (s, 9H), 1.2
0-1.95 (m, 14H), 2.17 (dd, J = 1
8.3, 7.1 Hz, 1H), 2.16-2.26
(M, 1H), 2.60-2.75 (m, 4H), 3.
23 (s, 2H), 3.75 (s, 3H), 4.22
(M, 1H) IR (neat); 2953, 2874, 2858, 2
234, 1746, 1462, 1436, 1411, 1
376,1281,1258,1234,1119,1
058, 1007, 877, 837, 778, 743,
670 cm -1 .
【0127】(2)上記(1)で得られた化合物を用
い、実施例1(3)と実質的に同様にして、3−チア−
16,17,18,19,20−ペンタノル−15,1
5−テトラメチレン−13,14−ジデヒドロ−PGF
1α メチルエステル 11−tert−ブチルジメチ
ルシリル−15−トリエチルシリル エーテルおよび3
−チア−16,17,18,19,20−ペンタノル−
15,15−テトラメチレン−13,14−ジデヒドロ
−PGF1β メチルエステル 11−tert−ブチ
ルジメチルシリル−15−トリエチルシリル エーテル
を得た。(2) Using the compound obtained in the above (1), 3-thia-thiazole was prepared in substantially the same manner as in Example 1 (3).
16,17,18,19,20-Pentanol-15,1
5-tetramethylene-13,14-didehydro-PGF
1 α methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether and 3
-Thia-16,17,18,19,20-pentanor-
15,15 give tetramethylene 13,14-didehydro-PGF 1 beta methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether.
【0128】3−チア−16,17,18,19,20
−ペンタノル−15,15−テトラメチレン−13,1
4−ジデヒドロ−PGF1α メチルエステル 11−
tert−ブチルジメチルシリル−15−トリエチルシ
リル エーテル1 H−NMR(CDCl3,200MHz)δppm;
0.10(s,3H),0.11(s,3H),0.5
6−0.72(m,6H),0.86−1.02(m,
9H),0.89(s,9H),1.20−2.08
(m,17H),2.46(dd,J=8.6,2.4
Hz,1H),2.52(d,J=9.2Hz,1
H),2.66(t,J=7.0Hz,2H),3.2
3(s,2H),3.74(s,3H),4.10−
4.20(m,1H),4.25−4.33(m,1
H) IR(neat);3468,2952,2930,2
874,2857,2231,1739,1462,1
436,1412,1388,1361,1278,1
257,1116,1057,1007,971,87
1,837,778,743cm-1。3-thia-16,17,18,19,20
-Pentanor-15,15-tetramethylene-13,1
4-didehydro-PGF 1 alpha methyl ester 11-
tert-butyldimethylsilyl-15-triethylsilyl ether 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.10 (s, 3H), 0.11 (s, 3H), 0.5
6-0.72 (m, 6H), 0.86-1.02 (m,
9H), 0.89 (s, 9H), 1.20-2.08
(M, 17H), 2.46 (dd, J = 8.6, 2.4)
Hz, 1H), 2.52 (d, J = 9.2 Hz, 1
H), 2.66 (t, J = 7.0 Hz, 2H), 3.2
3 (s, 2H), 3.74 (s, 3H), 4.10-
4.20 (m, 1H), 4.25-4.33 (m, 1
H) IR (neat); 3468,2952,2930,2
874, 2857, 2231, 1739, 1462, 1
436,1412,1388,1361,1278,1
257, 1116, 1057, 1007, 971, 87
1,837,778,743 cm -1 .
【0129】3−チア−16,17,18,19,20
−ペンタノル−15,15−テトラメチレン−13,1
4−ジデヒドロ−PGF1β メチルエステル 11−
tert−ブチルジメチルシリル−15−トリエチルシ
リル エーテル1 H−NMR(CDCl3,200MHz)δppm;
0.08(s,3H),0.09(s,3H),0.5
7−0.74(m,6H),0.82−1.03(m,
9H),0.89(s,9H),1.00−1.92
(m,18H),2.22(dd,J=9.4,6.6
Hz,1H),2.65(t,J=7.0Hz,2
H),3.23(s,2H),3.74(s,3H),
3.92−4.05(m,1H),4.06−4.30
(m,1H) IR(neat);3435,2953,2930,2
874,2857,2234,1739,1462,1
436,1412,1378,1361,1282,1
256,1121,1058,1007,880,83
7,778,744,670cm-1。3-thia-16,17,18,19,20
-Pentanor-15,15-tetramethylene-13,1
4-didehydro-PGF 1 beta methyl ester 11-
tert-butyldimethylsilyl-15-triethylsilyl ether 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.08 (s, 3H), 0.09 (s, 3H), 0.5
7-0.74 (m, 6H), 0.82-1.03 (m,
9H), 0.89 (s, 9H), 1.00-1.92
(M, 18H), 2.22 (dd, J = 9.4, 6.6)
Hz, 1H), 2.65 (t, J = 7.0 Hz, 2
H), 3.23 (s, 2H), 3.74 (s, 3H),
3.92-4.05 (m, 1H), 4.06-4.30
(M, 1H) IR (neat); 3435, 2953, 2930, 2
874, 2857, 2234, 1739, 1462, 1
436,1412,1378,1361,1282,1
256, 1121, 1058, 1007, 880, 83
7,778,744,670 cm -1 .
【0130】(3)上記(2)で得た3−チア−16,
17,18,19,20−ペンタノル−15,15−テ
トラメチレン−13,14−ジデヒドロ−PGF1α
メチルエステル 11−tert−ブチルジメチルシリ
ル−15−トリエチルシリルエーテルを用い、実施例1
(4)と実質的に同様にして、標記化合物を得た。(3) 3-thia-16, obtained in the above (2)
17,18,19,20- Pentanoru -15,15- tetra methylene-13,14-didehydro -PGF 1 α
Example 1 Using methyl ester 11-tert-butyldimethylsilyl-15-triethylsilyl ether
The title compound was obtained in substantially the same manner as (4).
【0131】1H−NMR(CDCl3,300MHz)
δppm;1.50−2.32(m,20H),2.6
7(t,J=6.8Hz,2H),3.24(s,2
H),3.75(s,3H),3.89−3.99
(m,1H),4.31−4.40(m,1H) IR(neat);3400,2945,2859,2
235,1734,1437,1384,1283,1
219,1136,1088,996,907,543
cm-1。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.50-2.32 (m, 20H), 2.6
7 (t, J = 6.8 Hz, 2H), 3.24 (s, 2
H), 3.75 (s, 3H), 3.89-3.99.
(M, 1H), 4.31-4.40 (m, 1H) IR (neat); 3400, 2945, 2859, 2
235,1734,1437,1384,1283,1
219, 1136, 1088, 996, 907, 543
cm -1 .
【0132】実施例18 3−チア−9−デオキシ−9β−クロロ−16,17,
18,19,20−ペンタノル−15,15−テトラメ
チレン−13,14−ジデヒドロ−PGF1α(化合物
43) 実施例17で得た化合物を用い、実施例2と実質的に同
様にして、標記化合物を得た。Example 18 3-Thia-9-deoxy-9β-chloro-16,17,
18,19,20- Pentanoru -15,15- compounds used obtained in tetramethylene-13,14-didehydro-PGF 1 alpha (Compound 43) Example 17, in substantially the same manner as in Example 2, the title The compound was obtained.
【0133】1H−NMR(CDCl3,300MHz)
δppm;1.50−2.00(m,17H),2.1
0−2.35(m,4H),2.65−2.75(m,
2H),3.22(s,2H),3.89−3.99
(m,1H),4.30−4.38(m,1H) IR(neat);3368,2935,2859,2
235,1708,1438,1383,1283,1
221,1071,991,947,905,793,
724,678,542cm-1。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.50-2.00 (m, 17H), 2.1
0-2.35 (m, 4H), 2.65-2.75 (m, 4H)
2H), 3.22 (s, 2H), 3.89-3.99.
(M, 1H), 4.30-4.38 (m, 1H) IR (neat); 3368, 2935, 2859, 2
235,1708,1438,1383,1283,1
221,1071,991,947,905,793,
724,678,542 cm -1 .
───────────────────────────────────────────────────── フロントページの続き (72)発明者 田中 英雄 東京都豊島区高田3丁目24番1号 大正製 薬株式会社内 (72)発明者 小野 直哉 東京都豊島区高田3丁目24番1号 大正製 薬株式会社内 (72)発明者 八木 慎 東京都豊島区高田3丁目24番1号 大正製 薬株式会社内 Fターム(参考) 4C086 AA03 DA02 DA04 NA14 ZA33 ZA36 ZA40 ZA42 ZC41 4H006 AA01 AB20 AB23 UE12 UE14 UE16 UE31 UE32 UE52 ──────────────────────────────────────────────────続 き Continued on the front page (72) Inventor Hideo Tanaka 3-24-1, Takada, Toshima-ku, Tokyo Taisho Pharmaceutical Co., Ltd. (72) Inventor Naoya Ono 3-24-1, Takada, Toshima-ku, Tokyo Taisho Pharmaceutical Co., Ltd. (72) Inventor Shin Yagi 3-24-1, Takada, Toshima-ku, Tokyo Taisho Pharmaceutical Co., Ltd. F-term (reference) 4C086 AA03 DA02 DA04 NA14 ZA33 ZA36 ZA40 ZA42 ZC41 4H006 AA01 AB20 AB23 UE12 UE14 UE16 UE31 UE32 UE52
Claims (3)
ランスビニレン基、エチニレン基、OCH2又はS
(O)pCH2を示し、Rは水素原子、C1-10の直鎖又は
分枝鎖状のアルキル基又はC3-10のシクロアルキル基を
示し、mは0〜5の整数を示し、nは1〜8の整数を示
し、pは0〜2の整数を示す。)で表されるプロスタグ
ランジン誘導体、その製薬学的に許容される塩又はそれ
らの水和物。(1) Formula (1) (Wherein, X represents a halogen atom, A represents an ethylene group, a transvinylene group, an ethynylene group, OCH 2 or S
(O) p CH 2 , R represents a hydrogen atom, a C 1-10 linear or branched alkyl group or a C 3-10 cycloalkyl group, and m represents an integer of 0-5. , N represents an integer of 1 to 8, and p represents an integer of 0 to 2. ), A pharmaceutically acceptable salt thereof or a hydrate thereof.
が1〜6の整数であり、pが0〜2の整数である請求項
1に記載のプロスタグランジン誘導体、その製薬学的に
許容される塩又はそれらの水和物。2. In the formula (I), m is 2 to 4;
Is an integer of 1 to 6, and p is an integer of 0 to 2. The prostaglandin derivative, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
原子であり、mが2〜4であり、nが1〜6の整数であ
り、pが0〜2の整数である請求項1に記載のプロスタ
グランジン誘導体、その製薬学的に許容される塩又はそ
れらの水和物。3. In the formula (I), X is a chlorine atom or a bromine atom, m is 2 to 4, n is an integer of 1 to 6, and p is an integer of 0 to 2. 2. The prostaglandin derivative according to 1, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11076837A JP2000273083A (en) | 1999-03-19 | 1999-03-19 | Prostaglandin derivative |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11076837A JP2000273083A (en) | 1999-03-19 | 1999-03-19 | Prostaglandin derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000273083A true JP2000273083A (en) | 2000-10-03 |
Family
ID=13616798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP11076837A Pending JP2000273083A (en) | 1999-03-19 | 1999-03-19 | Prostaglandin derivative |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2000273083A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004014394A1 (en) * | 2002-08-09 | 2004-02-19 | Taisho Pharmaceutical Co.,Ltd. | Antipruritic agent |
WO2004043471A1 (en) * | 2002-11-13 | 2004-05-27 | Taisho Pharmaceutical Co., Ltd. | Antipruritic drug |
US7737182B2 (en) | 2002-08-09 | 2010-06-15 | Taisho Pharmaceutical Co., Ltd. | Pharmaceuticals for xerosis |
-
1999
- 1999-03-19 JP JP11076837A patent/JP2000273083A/en active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004014394A1 (en) * | 2002-08-09 | 2004-02-19 | Taisho Pharmaceutical Co.,Ltd. | Antipruritic agent |
US7718701B2 (en) | 2002-08-09 | 2010-05-18 | Taisho Pharmaceutical Co., Ltd. | Antipruritic agent |
US7737182B2 (en) | 2002-08-09 | 2010-06-15 | Taisho Pharmaceutical Co., Ltd. | Pharmaceuticals for xerosis |
WO2004043471A1 (en) * | 2002-11-13 | 2004-05-27 | Taisho Pharmaceutical Co., Ltd. | Antipruritic drug |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100526282B1 (en) | Difluoroprostaglandin derivatives and their use | |
HU187398B (en) | Process for producing carbocylic compounds and pharmaceutical products containing these ones | |
JPH0369899B2 (en) | ||
JP4354644B2 (en) | Prostaglandin derivatives | |
WO2001012596A1 (en) | Prostaglandin derivatives | |
HU191057B (en) | Process for the production of new carbacycline-derivatives and of the pharmaceutical preparations containing them | |
EP0044711B1 (en) | 9,11-methano-13-aza-11a-carbathrombanoic acid analogues and pharmaceutical use thereof | |
JP3162668B2 (en) | ω-cycloalkyl-prostaglandin E2 derivative | |
JP2000273083A (en) | Prostaglandin derivative | |
US5057621A (en) | 11-substituted-16-phenoxy and 16-substituted phenoxy-prostatrienoic acid derivatives | |
JP4563636B2 (en) | Prostaglandin derivatives | |
JPS624390B2 (en) | ||
HU200173B (en) | Process for producing intermediary products of prostaglandin analogs | |
JPS5823393B2 (en) | prostaglandin | |
JPH07285929A (en) | Prostaglandin derivative | |
US5416231A (en) | Prostaglandin I2 derivatives | |
JPH05117230A (en) | Prostaglandin derivative | |
JPH06192218A (en) | Prostaglandin derivative | |
JP2001089443A (en) | Prostaglandin derivative | |
JP2000273082A (en) | Prostaglandin derivative | |
JP3310301B2 (en) | Intermediate for synthesis of vitamin D and steroid derivatives and method for producing the same | |
JP2001122786A (en) | Sleep-inducing agent | |
JP3316050B2 (en) | Prostaglandin E1 analog | |
HU192316B (en) | Process for producing new carbacyclin derivatives and pharmaceutical compositions containing them | |
JP2001139544A (en) | Prostaglandin derivative |